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Background: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis 
(NASH) have been associated with the rise in metabolic diseases. Inflammation and oxidative 
stress are key mediators in NAFLD development. Current therapeutics used to treat NAFLD 
include insulin sensitisers and vitamin E. Afriplex GRT extract was previously showed to 
decrease inflammation and oxidative stress in cardiac cells. The study aimed to assess if 
Afriplex GRT extract could protect against hepatic oxidative stress, apoptosis and 
inflammation in in vitro and in vivo NAFLD models. Methods: Liver steatosis was induced in 
vitro by exposing HepG2/C3A human liver cells to 1 mM oleic acid for 24 h. Anti-steatotic 
effects of Afriplex GRT [1, 10 and 100 μg/mL] and/or Pioglitazone [30 μM] were determined 
in mono- and co-treatments for 24 hrs post induction of steatosis. The 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay was performed to determine cell 
metabolic activity and viability. An Oil red O assay was used to quantify the intracellular lipid 
content of the treated C3A cells in vitro. Liver samples were obtained from a previous study, 
which used C57BL/6 mice with hepatosteatosis treated with or without Afriplex GRT [74 and 
740 mg/kg] and pioglitazone [15 mg/kg] for ten weeks. Both in vitro and in vivo models were 
analysed for the expression of genes and proteins associated with the development of NAFLD 
(AKT, AMPK-α, TNF-α, SOD2, IRS1, PPAR-α, SREBF1, ChREBP and FASN) using qRT-
PCR and Western blot analysis. Results: Treatment with oleic acid experimentally induced 
steatosis in C3A cells (p < 0.01), as confirmed by Oil red O staining. Afriplex GRT treated 
cells showed a reduction in fat accumulation in a dose-dependent manner. Furthermore, co-
treatment with pioglitazone was shown to be effective (p < 0.05). Genes involved in lipid 
metabolism (SREBF1, ChREBP and FASN) were suppressed by treatment with Afriplex GRT, 
contributing to reduced lipid content in both models. Afriplex GRT also induced a reduction 
in the expression of SOD2 and the inflammatory cytokine (TNF-α). Conclusion: Afriplex GRT 
reduces hepatic steatosis in C3A cells and C57BL/6 mouse liver by modulating SREBF1, 
ChREBP and FASN gene expression. The extract also affected the expression of oxidative 
stress and inflammation related genes in both models, through the reduced gene expression of 





Agtergrond: Nie-alkoholiese vetterige lewersiekte (NAFLD) en nie-alkoholiese 
steatohepatitis (NASH) word geassosieer met die toename in metaboliese siektes. Inflammasie 
en oksidatiewe stres is van die hoof oorsake in die ontwikkeling van NAFLD. Huidige terapieë 
wat gebruik word vir die behandeling van NAFLD sluit insulien-sensitiseerders en vitamien E 
in. Voorheen is getoon dat Afriplex GRT inflammasie en oksidatiewe stres in hartselle 
verminder. Hierdie studie het ten doel gehad om te bepaal of Afriplex GRT ekstrak en 
pioglitazone, lewerselle kan beskerm teen oksidatiewe stress, apoptose en inflammasie in 
modelle van NAFLD. Metodes: Lewersteatose is in HepG2/C3A menslike lewerselle 
geïnduseer deur hulle met 1 mM oliesuur vir 24 uur te behandel. Anti-steatotiese effekte van 
Afriplex GRT [1, 10 en 100 μg/mL] en / of pioglitazone [30 μM] is bepaal 24 uur na steatose-
induksie, beide as mono- en kombinasie behandelings. Lewermonsters afkomstig van 'n vorige 
studie waarin C57BL/6-muise vir tien weke lank behandel is met Afriplex GRT [74 en 740 
mg/kg] en pioglitazone [15 mg/kg] is gebruik om die ekspressie van gene en proteïene wat 
verband hou met die ontwikkeling van NAFLD (AKT, AMPK-α, TNF-α, SOD2, IRS1, PPAR-
α, SREBF1, ChREBP en FASN) deur qRT-PCR en Western blot te ondersoek. Resultate: In 
vitro veroorsaak oleïensuur steatose in C3A-selle (p <0.01). Afriplex GRT-behandelde selle 
het 'n konsentrasie-afhanklike afname van vet akkumulasie getoon. Verder is getoon dat die 
kombinasie van pioglitazone en Afriplex GRT (p <0.05) meer effektief was. Gene wat betrokke 
is by lipiedmetabolisme (SREBF1, ChREBP en FASN) was deur Afriplex GRT in beide 
modelle verlaag. Afriplex GRT het ook oksidatiewe stres (SOD2) en inflammasie (TNF-α) 
verminder. Gevolgtrekking: Afriplex GRT verminder hepatiese steatose in C3A-selle en in 
C57BL/6-muise se lewers deur die modulering van SREBF1, ChREBP en FASN 
geenuitdrukking. Die ekstrak beskerm ook teen oksidatiewe stres en inflammasie deur die 
geenekspressie van SOD2 en TNF-α te verlaag, wat daarop dui dat Afriplex GRT 'n terapeutiese 
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Non-alcoholic fatty liver or hepatic steatosis refers to the excessive cumulative influx of free 
fatty acids (FFAs) into hepatocytes 1. FFAs play a pivotal role in many cellular processes which 
include cellular membrane synthesis, storage of energy in adipocytes, as well as intracellular 
signalling pathways. An uncontrolled build-up of FFAs disrupts the efficiency of metabolic 
pathways and may cause organs such as liver to become resistant to insulin 2. As hepatocytes 
become inflated with fatty acids, the surface area of those hepatocytes become bigger, leading 
to compression of nearby hepatocytes. The compression of hepatocytes may lead to 
inflammatory response that lead to tissue damage comparable with what is observed with 
secondary causes of liver fat accumulation such as excessive consumption of alcohol or side 
effects related to the consumption of modern therapeutics 3, 4.  
Only when the fat accumulation of the liver exceeds 5% of the total organ mass, it can be 
defined as a “fatty liver” 5. A number of pathophysiological mechanisms trigger hepatic 
steatosis. These include reduced fatty acid β-oxidation by the mitochondria, endogenous fatty 
acid synthesis, increased delivery of fatty acids to the liver as well as indigent exporting and 
integrating lipids within hepatocytes 6. Furthermore, constant accumulation of FFAs in the liver 
results in lipoperoxidative stress and hepatic damage 2. The two pathways involved in the 
metabolism of FFAs that are processed by the liver to generate energy in the form of ATP or 
produce triglycerides are known as oxidation and esterification. These pathways are essentially 
responsible for the genesis of very low-density lipoprotein (VLDL) particles 7. 
Hostile and long-term consequences of the metabolism arise from physiologically unregulated 
overall rate of hepatic FFA uptake, which is linked directly to FFA concentrations in the liver. 
Along with being one of the largest internal organs in the body, the liver also plays a vital role 
in metabolising lipids by importing and exporting FFAs. The liver regulates FFAs by 
synthesizing lipids when there is a shortage and storing lipids when in abundance, however the 
burden laid upon the hepatic system through the increased flux of FFAs in the system may 
cause/lead to severe and/or complex complications beyond hepatic steatosis such as non-
alcoholic fatty liver disease (NAFLD) 8. 
The increase in the number of diabetes and obesity diagnosis contributes to the increase in 
NAFLD cases to about 1.8 billion of the global population 9. Effects brought upon by hepatic 
FFA induced insulin resistance causes inflammation and apoptosis, as the disease progresses 
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10. NAFLD-associated insulin resistance is linked to hyperlipidaemia, due to the restriction of 
the anti-lipolytic action of insulin 11,12. The imbalance of adiponectin and tumour necrosis 
factor α (TNF-α), secreted by the adipose tissues has been linked to the development of insulin 
resistance-associated NAFLD. This alters the insulin signalling pathway leading to the 
increased flux of FFAs into the liver 13. Of concern is the progressive nature of NAFLD to a 
recurrent liver disorder around the globe as the disease may ultimately progress into non-
alcoholic steatohepatitis (NASH), which is an even more severe condition 9. Hepatic oxidative 
stress contributes to the “second hit” of NAFLD progression. Microsomal and peroxisomal 
fatty acid oxidation is a key component in the progression of the disease through oxidative 
stress. This coupled with mitochondrial dysfunction and lipid peroxidation has been regarded 
as major contributors of reactive oxygen species (ROS) generation in the liver 14. Furthermore, 
without treatment and diet change, these conditions are likely to manifest into progressive 
chronic hepatic injury, for instance, liver fibrosis (cirrhosis) and at the worst hepatocellular 
carcinoma 15. 
Thiazolidinediones (TZDs) exhibit anti-inflammatory properties in patients with 
steatohepatitis by the suppression of pro-inflammatory pathways 16. As such, these are 
responsible for the reversal of these abnormalities by resolving effects of insulin resistance in 
adipose tissues, the liver and skeletal muscles. A TZD derivative, known as pioglitazone, 
functions as a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist and insulin 
sensitizer. Pioglitazone is currently used to treat patients diagnosed with type-2 diabetes 
mellitus (T2DM). A placebo-controlled trial study has shown that this drug improves the 
metabolism of glucose and lipids in diabetic patients by counteracting the effects of insulin 
resistance 17. Pioglitazone reduces blood sugar and lipid levels in hepatic steatosis, which 
makes it appropriate to treat T2DM patients as well as those with hepatic steatosis 18. 
Unfortunately, pioglitazone is known to contribute to tumours of the bladder and its use has 
since been withdrawn as a form of treatment in some countries 17,19. 
Pioglitazone is a synthetic ligand for peroxisome proliferator-activated receptors (PPARs). 
These are transcription factors responsible for altering the transcription of genes and therefore 
influencing the metabolism of lipids and carbohydrates 20. This, therefore allows a change in 
the amount of proteins that are synthesised, which then leads to metabolic changes in the 
presence of the drug 21. Moreover, pioglitazone improves glycaemic control in patients with 
diabetes by its action on receptors PPAR-γ-1 and PPAR-γ-2, which enhances the body’s 
sensitivity towards insulin. Other action of pioglitazone is exerted on PPAR-α and this is 
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associated with improved lipid metabolism. The interaction of ligands such as pioglitazone to 
respective receptors has shown to cause an increase in the uptake of glucose and its utilisation 
in surrounding organs, thereby decreasing gluconeogenesis effects in the liver and eventually 
reducing insulin resistance 21. 
Aspalathus linearis, commonly referred to as rooibos, naturally grows in the Western Cape’s 
greater Cederberg region in South Africa. The fynbos biome hosts this flowering shrub in 
abundance and locals have used this plant as a herbal tea by crushing the plants stems and 
leaves. This now commercialized herbal tea has been a research subject over the years for its 
use in traditional regiments 22 and research has identified the crops constituents, as significant 
quantities of polyphenolic compounds and antioxidants have been identified 23. Rooibos is of 
interest to phytochemical research as it hosts numerous antioxidant-associated health benefits 
such as anti-viral properties as well as anti-mutagenic and anti-inflammatory effects 24. In 
addition, rooibos has been previously reported to have hypolipidemic, anti-diabetic and anti-
inflammatory activities attributed to bioactive compounds such as; aspalathin (a C-linked 
dihydrochalcone glucoside) and Z-2-(β-D-glucopyranosyloxy)-3-phenylpropenoic acid 
(PPAG) 25. Globally, the use of herbal products such as rooibos and traditional medicines as a 
natural form of health care, is also becoming prevalent in developing countries 26. 
Current pharmaceuticals are costly and harbour a number of unpleasant side effects. Although 
some anti-diabetic drugs are used to treat NAFLD, plant-derived polyphenols are gaining 
recognition as potential therapies, which harbour less side effects, with their use 
complementary to current therapies being an option 27. The potential that rooibos possesses by 
its action on lipid metabolism, amongst a host of other antioxidant related benefits, may 





2. Literature Review 
2.1 The metabolic syndrome and hepatic steatosis 
The metabolic syndrome is described as a cluster of metabolic derangements that, ultimately 
increase the risk of heart disease, T2DM, stroke and liver dysfunction 28,29. These metabolic 
derangements include hyperglycaemia, dyslipidaemia, inflammation, obesity and increased 
blood pressure 28. The metabolic syndrome is linked to obesity and insulin resistance, which 
increase liver dysfunction through the increased flux of lipids in the body 29. Fatty liver or 
hepatic steatosis is identified as the most common type of liver disease, caused by the abnormal 
retention of FFAs in hepatocytes, leading to moderate to severe hepatocellular injury 30. The 
occurrence of this disorder has revealed that metabolic syndrome, more specifically, insulin 
resistance associated with T2DM and obesity are the major causes of the NAFLD 31. 
Physiological changes observed in patients with NAFLD have been reported to be the result of 
insulin resistance and obesity 32. Obese patients challenged with insulin resistance are therefore 
faced with the inability to process increased blood glucose and triglyceride levels 33. This 
further deteriorates the hepatic system, contributing to the pathogenesis of simple steatosis to 
NAFLD, as increased adipose tissue lipolysis causes the release of FFAs into circulation 34. 
2.1.1 The effect of dyslipidaemia in NAFLD development 
Patients plagued with NAFLD often have other features of the metabolic syndrome, in this 
case, dyslipidaemia, insulin resistance, diabetes and obesity are highlighted as risk factors 
associated with NAFLD 3135. Dyslipidaemia in NAFLD is characterised by the increase in 
serum triglycerides and increased low-density lipoprotein (LDL) coupled with the decreased 
levels of high-density lipoproteins (HDL) 36.  
The pathogenesis of dyslipidaemia in NAFLD has not yet been fully elucidated, although the 
imbalance in cholesterol concentrations has shown to increase the likelihood of the 
development of cardiovascular disease and steatohepatitis 37. NAFLD is also characterised by 
atherogenic dyslipidaemia, postprandial lipidemic and HDL-dysfunction 38. It was reported 
that, although HDL exerts beneficial pleiotropic properties, in the presence of dysglycaemia, 
oxidative stress and/or inflammation, HDL particles may be transformed into dysfunctional 
molecules exerting pro-atherogenic effects 39.  
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A study consisting of sixteen patients with NAFLD and twenty four control subjects 
demonstrated that patients with fatty liver disease have significant abnormal imbalance of body 
cholesterols, that results in atherogenic traits, mainly caused by the hepatic overproduction of 
very low-density lipoprotein (VLDL) particles into the circulation 40. Dietary cholesterol intake 
constantly exposes the liver to free cholesterols. Therefore, the liver contributes directly to 
cholesterol homeostasis. The dysregulation of cholesterol homeostasis has been previously 
reported in patients with NAFLD 41,42. Hepatocytes mainly acquire cholesterol through 
mitochondrial and/or cytoplasmic oxidation reactions, where acetyl-CoA and acetoacetyl-CoA 
are converted to 3-hydroxy- 3-methylglutaryl-CoA (HMG-CoA) by HMG-CoA synthase, 
contributing to cholesterol biosynthesis 43. 
2.1.2 Insulin resistance-associated NAFLD and diabetes mellitus 
Insulin resistance occurs when the body is unable to respond to insulin, which is secreted by 
the pancreas in response to increased blood glucose levels. Previous studies have highlighted 
how NAFLD is associated with the increase in insulin resistance when compared to controls, 
as the findings showed how insulin resistance increases with an increased degree of steatosis 
44,45. Insulin resistance-associated NAFLD has also been associated with hyperlipidaemia, as 
the body’s inability to effectively utilise insulin restricts the hormones’ anti-lipolytic action 
11,12. Due to insulin resistance, the liver reportedly experiences an increase in glycolysis, 
subsequently decreasing apolipoprotein B-100 which inhibits the exportation of VLDL 
particles 7. The development of insulin resistance-associated NAFLD has been linked to the 
imbalance of adiponectin and tumour necrosis factor α (TNF-α) cytokines secreted by the 
adipose tissues. Through the inhibition of insulin-stimulated glucose uptake and glycogen 
synthesis in the liver, an alteration in the insulin signalling pathway to fatty acid stimulated 
insulin signalling as a compensation is observed, which favours increased flux of free fatty 
acids (FFAs) thus owing to insulin resistance 13. 
Patients that suffer from NAFLD without any risk factors associated with the metabolic 
syndrome, account for 16% of the NAFLD prevalence 35,46,47. On the contrary, the prevalence 
is higher in high-risk patients such as obese patients (91%), individuals with hyperlipidaemia 
accounting for 90% and diabetics accounting for 60% 7. Diabetes mellitus is a major risk factor 
in the obesity endemic, with obese diabetics facing the risk of developing microvascular and 
macrovascular complications, that may eventually contribute to hepatic insulin resistance 12. 
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There are two known types of diabetes mellitus, type 1 diabetes mellitus (T1DM) and T2DM. 
T1DM patients are unable to produce insulin, whereas T2DM patients are affected by body’s 
inability to respond to increased levels of blood glucose, either by producing insufficient 
insulin or the action of insulin is impeded 48. It is reported that approximately 10% of all 
diabetes cases are T1DM, and the remaining 90% of the cases are classified as T2DM 48. 
NAFLD development and progression may be associated with insulin resistance and diseases 
such as diabetes and obesity, but not all NAFLD patients are diabetic or obese. In fact, there is 
evidence in literature that indicates that NAFLD occurs in non-diabetic patients, therefore there 
may be other factors contributing to NAFLD development suggesting that insulin resistance 
may not be the determining factor of NAFLD severity 49. 
2.1.3 The role of obesity in hepatic steatosis 
The imbalance in energy intake and energy expenditure results in a pathological white adipose 
tissue remodelling, characterized by adipocyte hypertrophy, chronic inflammation, and fibrosis 
leading to obesity. Obesity is mainly caused by a high caloric diet, as studies have shown that 
a lack of exercise coupled with a poor diet leads to excessive weight gain 50. In some cases, a 
genetic mutation may be the cause of a poor metabolism, owing to the cause. FFAs are 
absorbed into specialised connective tissues known as white adipose tissues, a mechanism 
which allows the body to transport excess FFAs away from vital organs such as the liver 51. In 
an obese state, this mechanism is altered therefore leading to an abnormal retention of FFAs in 
vital organs and their peripheral tissues. 
Implications that lead to the development of hepatic steatosis stem from the abnormal 
accumulation of FFAs in circulation. In obese patients, metabolic disturbances such as reduced 
insulin sensitivity and increased glycogen storage favour the development of NAFLD 52. The 
conversion of glucose to glycogen as a storage mechanism is used by the liver to compensate 
for increased or decreased blood glucose levels. Glucose is also converted to FFAs by the liver 
and the adipose tissues for long/short-term storage 51–53. In the liver, excessive storage of FFAs 
causes hypertrophy of the hepatocyte and ultimately steatosis. 
Steatosis of the liver may be instigated by a number of other pathophysiological mechanisms 
that include reduced β-oxidation by the mitochondria due to mitochondrial dysfunction, an 
enhanced flux of dietary FFAs into hepatocytes, as well as the poor exportation of FFAs from 
hepatocytes and de novo lipogenesis 54. This hepatic manifestation is concerning as the global 
burden has spiked due to the constant rise in metabolic related diseases. An assessment was 
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published as early as 2018, where they reported the estimated global prevalence of NAFLD to 
a 25% incidence in the global population 55. Their findings highlighted a few regional 
differences, with the most cases reported in the South American continent as well as countries 
in the Middle East and the least cases reported in Africa 55,56. This has therefore made NAFLD 
the most common chronic liver disease worldwide, predicted to become the main cause of 
cirrhosis and denoting this disease as the hepatic manifestation of the metabolic syndrome 57. 
2.2 Pathogenesis of non-alcoholic fatty liver disease 
NAFLD is induced by simple steatosis and is regarded as the manifestation of physiological 
processes that cause a build-up of lipids in the hepatic tissue, which is not related to excessive 
alcohol consumption. Its pathogenesis is a result of numerous factors, which are highlighted 
by an interplay of metabolic pathways involved in de novo lipogenesis, gluconeogenesis, β-
oxidation, the secretion of cytokines and poor sensitivity by a host of receptors. The exact 
mechanism by which NAFLD develops or progresses still remains a topic in research, with no 
definitive mechanism elucidated 58. NAFLD underlies more severe conditions such as NASH 
59, and without effective intervention it may progress into irreversible hepatic injury such as 
liver fibrosis (cirrhosis) and potentially hepatocellular carcinoma (Fig. 2.1) 15.  
 





Seventy five to a hundred million American individuals were reportedly affected by NAFLD 
in 2017, making up to an estimated 40% of the adult population in the United States, with 12% 
accounting for individuals living with NASH 56. Limited data on the prevalence of NAFLD is 
available in Africa. In 2019 Paruk et al., reported that amongst patients with T2DM the 
prevalence of NAFLD by non-invasive ultrasound, was 10% to 69% in Nigeria, 50% in Sudan 
and 73% in Ethiopia 60. In South Africa a study conducted on obese patients in the Western 
Cape, reported a prevalence of NAFLD (48%) 61. NASH is described as condition more severe 
than hepatic steatosis, where studies show an intense build-up of FFAs in the liver, leading to 
the hypertrophy and inflammation of hepatocytes 15. The main cause of NASH, like in NAFLD, 
is not related to the excessive consumption of alcohol. In fact evidence has substantiated the 
severity of the condition with increased absorption of FFAs into hepatocytes, substantial 
inflammation of the hepatic tissue with increased scarring, contributing to the reduction of liver 
functionality 15.  
According to the “two-hit” theory of NAFLD pathogenesis, increased FFAs into the portal 
system along with increased lipogenesis and decreased β-oxidation  are the initial steps to 
hepatic steatosis induction 62. The “second hit” occurs as a result of increased cytokines, 
endotoxins as well as reactive oxygen species (ROS), contributing to the progression of 
NAFLD to NASH 63. Most patients take years to develop NASH from hepatic steatosis. 
Evidence therefore, demonstrates that NAFLD is indeed a multisystem disease, affecting extra-
hepatic organs through the regulation of metabolic pathways involved in hepatocellular 
homeostasis 64. 
2.2.2 Liver fibrosis 
Liver fibrosis is the end-stage of a spectrum of chronic liver conditions, sharing features of 
necroinflammation and altered regenerative nodules, all of which reduce the normal structure 
of the liver to reduced functional mass and the degradation in vascular architecture 65. 
Currently, the most common aetiologies for liver fibrosis are, alcoholic-related liver disease 
(ALRD) and NAFLD, steatohepatitis as well as chronic hepatitis-B and hepatitis-C 66. 
In a group of individuals with NASH, forty-fifty percent of these individuals will reportedly 
develop hepatic fibrosis 64. An increased risk in liver related deaths were reported to be 5-10 
fold depending on the severity of the condition in a meta-analysis of 40 studies, owing to the 
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rate at which each patient develops fibrosis 64. In 2009, patients with steatohepatitis accounted 
for 10% of the average patients listed for liver transplantation in developed countries 67. 
Substantial evidence has shown that liver fibrosis and cirrhosis are the common causes of the 
development of hepatic carcinoma. Individuals with NAFLD-induced liver fibrosis have 
increased chances of developing hepatic carcinoma compared to patients with other aetiologies 
of liver fibrosis 68. NAFLD is fast becoming one of the leading causes of cirrhosis and hepatic 
carcinoma, whilst the prognosis of NAFLD-related cirrhosis is poor, the treatment of NAFLD 
should be highly emphasised well before the condition progresses to hepatic carcinoma. 
NAFLD pathogenesis elaborates on how severe and complex the disease may develop when 
left untreated. 
2.3 Effect of metabolic perturbations on NAFLD pathogenesis  
Fatigue is the most commonly experienced symptom in patients living with liver disease, partly 
due to the nature of the liver condition but more specifically as a result of changes in 
neurotransmission in the brain 69,70. NAFLD usually shows no symptoms however, fatigue and 
abdominal pain may be experienced by patients suffering from the disease. Patients with 
diabetes experience high blood glucose levels and in order to process this excess energy the 
body stores it in the liver as glycogen and as FFAs in adipose tissues 69,70. For the body to 
utilise this energy, the cell must first convert it to ATP (adenosine triphosphate) by converting 
pyruvate through the Krebs cycle to acetyl-CoA 69. A series of processes in the Krebs cycle 
leads to the production of palmitic acid, where acetyl-CoA is carboxylated to malonyl-CoA 
facilitated by acetyl-CoA carboxylase 1 (ACC1) catalysis, resulting in palmitic acid production 
through the enzyme fatty acid synthase (FASN) 71. The elongation and desaturation of the 
palmitic acid molecule leads to the synthesis of stearic acid, and further desaturation of the 
stearic acid molecule results in the production of oleic acid 69,71. Therefore, during hepatic 
steatosis there is an unparalleled surplus of FFA molecules, mainly the product of de novo fatty 
acid synthesis of oleic acid. Although there is a definitive pathway, which describes the 
synthesis of FFA molecules, the rate of this mechanism has been reported to be amplified by 




2.3.1 The role of lipogenesis in NAFLD 
Lipotoxicity is a major risk factor for patients with NAFLD due to ectopic lipid accumulation 
73. Mechanisms that are responsible for cellular homeostasis include the elimination of the 
overflow of lipids to prevent further liver functional complications. Dietary factors and de novo 
fatty acid synthesis are highly associated with the influx of FFAs into the circulation and the 
overall increased plasma fatty acid levels 72. This, along with the metabolic syndrome, 
contributes to the progression or worsening of the disease as the mechanisms involved in lipid 
degradation are ineffective in controlling the pathogenesis of NAFLD. 
Organelles involved in regulating the lipid overflow include the mitochondria and functional 
peroxisomes, which have a central role in lipid degradation, counteractively managing the 
abnormal accumulation of FFAs in hepatocytes during metabolic stress 74. Peroxisomes are 
specialised organelles involved in fatty acid oxidation, as substrate specificity of very long-
chain fatty acids and branched-chain fatty acids are directed to β-oxidation  and alpha-
oxidation, respectively 75.  
Increased insulin and blood glucose in circulation triggers de novo lipogenesis, leading to the 
abnormal retention of FFAs in hepatocytes. Sterol regulatory element-binding transcription 
factor-1 (SREBF1), has been reported to have a role in the development of hepatic steatosis 76. 
SREBF1 encodes for sterol regulatory element-binding protein-1c (SREBP-1c) in humans and 
is an isomer in a family of transcription factors which include, carbohydrate-response element-
binding protein (ChREBP) and PPAR-γ 76. SREBP-1c is a membrane-bound transcription 
factor responsible for lipogenesis, and as a result the increased triglyceride levels during 
steatosis is due to the modulation of genes involved in the triglycerides synthesis 77.  
Acetyl-CoA carboxylase 2 (ACC2) activation, an isomer of acetyl-CoA carboxylase (ACC), is 
regarded as a mode where SREBP-1c initiates FFA production 78. ACC is responsible for 
malonyl CoA production in the mitochondrial membrane, thereby contributing to the increase 
in malonyl CoA levels and leading to β-oxidation reduction 79. β-oxidation is strongly 
dependent on carnitine palmitoyl transferase-1, which is responsible for translocating FFAs 
into the mitochondria, therefore, carnitine palmitoyl transferase-1 inhibition prevents this 




By consequence of the increased FFAs, the inhibition or reduction of the above mentioned 
regulatory responses results in the rise of plasma FFA levels 78,79. Furthermore, SREBP-1c 
overexpression is highly associated with NAFLD development, by the amplification of hepatic 
fatty acid synthesis 76,77. 
2.3.2 Hepatic oxidative stress 
Hepatic oxidative stress is represented as a “second hit” in the pathogenesis of NASH. In 
NAFLD, microsomal and peroxisomal fatty acid oxidation, mitochondrial dysfunction as well 
as lipid peroxidation are regarded as major contributors to increased ROS production 14. 
Hepatic oxidative stress is reported as the major cause of NAFLD progression to 
steatohepatitis, (Fig. 2.2). 
 
Figure 2.2 Multiple hit model of NAFLD, illustrative of the response mechanisms of the pathogenesis, 
as NAFLD progresses to NASH (adapted from, James and Day 1). 
 
Homeostasis of lipid and glucose metabolism is regulated mainly by activities in the 
mitochondria, including β-oxidation, electron transfer and ATP production 80. The 
abnormalities in the mitochondria are primary causes for the altered balance between pro-
oxidant and anti-oxidant mechanisms, leading to the induction of ROS production 81. Under 
normal physiological conditions, the rate at which ROS and anti-oxidants are generated is 
balanced but in NAFLD and NASH this balance is disrupted 14. This is supported by evidence 
that suggests that mitochondrial dysfunction, through mitochondrial DNA damage, might be 
the instigator of the increased lipid accumulation and oxidative stress in the liver, progressing 
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NAFLD into steatohepatitis 82. Mitochondrial DNA damage has been analysed in previous 
studies, and the results show that the damaged nucleic genes are ultimately responsible for 
encoding mitochondrial proteins involved in the progressive increase of oxidative stress levels 
83. 
The endogenous antioxidant defences such as the enzymes catalase (CAT) and superoxidase 
dismutase 2 (SOD2) are responsible for the detoxification of ROS, by converting the 
superoxides and hydrogen peroxide into less toxic species 84. Clinical data show that this trait 
is deficient in patients with NASH along with the activity of glutathione s-transferases (GST), 
an enzyme involved in xenobiotic detoxification and the protection of hepatocytes against 
exogenous derived oxidative stress 85.  
Regulated expression levels of anti-oxidants, through hepatic oxidative stress, have been 
reported to contribute to the inflammation observed in NASH 57. A study by Nobili et al, 
showed that lipid oxidation produces signalling modulators during the progression of the 
disease to NASH, linking hepatic steatosis to necroinflammation by mechanisms of lipid 
peroxidation 86. The study used a methionine-choline deficient (MCD) diet on eight week-old 
male C57BL/6J mice to induce and characterise the possible involvement of adaptive immunity 
in NASH 57. Extensive liver injury and lobular inflammation were observed, and the results 
indicated that hepatic oxidative stress contributes to the progression of NAFLD to NASH by 
stimulating cellular immune responses, thus providing evidence of the possible role of adaptive 
immunity in the pathogenesis of the disease 86,87. 
2.3.3 Inflammatory response 
The systemic inflammatory response observed in NASH has supported evidence that the 
clinical burden of NAFLD is not only confined to liver-related morbidity and mortality but that 
NAFLD is a multisystem disease, affecting several extra-hepatic organs and regulatory 
pathways 64. Studying the pathophysiology of NAFLD has led to the discovery of various 
genomic aspects involved in the mild disease state and the pathogenesis into NASH, through 
the activation of inflammatory pathways 85. The cascade of events highlighted in the 
progression of the disease is linked to the nuclear factor-kappa B (NF-kB), TNF-α and 
interleukin 6 (IL-6), that are referred to as three of the major pro-inflammatory cytokines, that 




Reports in the literature have shown that TNF-α has a vital role in the initiation of hepatic 
insulin resistance, where the expansion of visceral adipose tissue stimulates its release 89. This 
activates a cascade of downstream inflammatory signalling kinases, namely, inhibitor kappa B 
kinase (IkK) and C-Jun-N-terminal kinase (JNK) 89. These events lead to the recruitment of 
downstream molecules, NF-kB and activator protein-1 (AP-1) resulting in the inhibition in the 
phosphorylation of insulin receptor substrate (IRS), which in turn impairs insulin signalling 
and leads to peripheral insulin resistance, (Fig. 2.3) 14. 
 
Figure 2.3 Inflammatory pathway involved in the regulation of insulin resistance (adapted from, Tilg 
and Moschen 14). TNF-Tumour necrosis factor, TNFR1- Tumour necrosis factor receptor 1, IL-6- 
Interleukin 6, IL-6Rα- Interleukin 6 receptor alpha, AdipoR1/2- Adiponectin receptor 1/2, TRADD- 
Tumor necrosis factor receptor type 1-associated DEATH domain protein, InsulinR- Insulin receptor, 
IRS- insulin receptor substrate, P- phosphorylated, ub- ubiquitin, STAT3- Signal transducer and 
activator of transcription 3, ROS- Reactive oxygen species, JNK- c-Jun N-terminal kinase, IKK-β- 
Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta, PPAR- Peroxisome proliferator-activated 
receptor, NFkB- Nuclear factor kappa B, AP-1- Activator protein 1. 
 
In addition, TNF-α decreases hepatocyte insulin sensitivity by reducing the overall expression 
of insulin-dependent glucose transporter (GLUT-4), along with the reduction in 
phosphorylation of IRS resulting to hepatic insulin resistance. Insulin resistance is also 
associated with an overall increase in the amount of FFAs circulating within the blood system 
11,90. The modulation of the increased FFAs in hepatocytes is led by lipogenic and lipolytic 
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genes FASN and SREBP-1c respectively 63. FASN, in response to hormone signalling is 
responsible for de novo lipogenesis, whereas SREBP-1c is a transcription factor that plays a 
major role in maintaining lipid homeostasis and regulating fatty acid metabolism 63. The 
transcriptional control of the genes involved in glycolysis and lipogenesis is altered with the 
increased expression of the TNF receptor, as there is an increased expression of SREBP-1c, 
impairing insulin sensitivity and contributing to the progression of NAFLD to NASH 91. 
Research has shown that the increased secretion of the hormone adiponectin by adipocytes acts 
as an anti-inflammatory substrate. Adiponectin is a hormone that is involved in regulating 
glucose levels and is a major product of adipocytes, which binds to its receptors adiponectin 
receptor 1 (ADIPOR1) and adiponectin receptor 2 (ADIPOR2). ADIPOR2 is located mainly 
in the liver and as adiponectin binds to ADIPOR2, it stimulates the secretion of anti-
inflammatory cytokines (IL-10), blocking NF-κB activation thereby inhibiting the release of 
TNF-α and IL-6 63. Findings show that adiponectin plays an important role in preventing liver 
steatosis, as it was observed to cause an upregulation of PPAR-α expression, resulting in further 
fatty acid oxidation 92. However, its hepatoprotective effects are not yet fully elucidated as the 
results demonstrate that TNF-α and adiponectin suppress and antagonise each other’s 
production and action in the target organ 92. 
2.3.4 Pro-apoptotic pathways 
NAFLD is caused by the increased flux of lipids into hepatocytes. Hepatocytes initially adapt 
to these increased levels by utilisation and storage mechanisms. However, through the 
progressive manifestation of the disease, cells develop inflammation and undergo lipid-induced 
cell death driven by activation of pro-apoptotic pathways 93  
Apoptosis is a mode of cell suicide essential for tissue homeostasis and removal of damaged 
cells from the body 94. It is characterised by morphological and biochemical features 95. During 
early apoptosis, phosphatidylserine (PS), a component of the cell membrane found within the 
inner leaflet of the cell’s lipid bilayer, becomes externalised by the flipping of the membrane, 
making the cell a target to scavenger receptors. This serves as an effective apoptosis marker 
identified by the binding of annexin-V 96. Furthermore, there is a formation of blebs within the 
cell’s mitochondrial membrane which causes a depolarisation of the mitochondrial membrane 
97. In the later stages, the cell loses its membrane integrity and chromosomal DNA is cleaved 
into oligonucleosomal sized fragments 95,97.  
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Apoptosis may occur in either of the two common pathways, the extrinsic and intrinsic pathway 
97. The extrinsic pathway of apoptosis is characterised by external stimuli which cause binding 
of death ligand (FasL) to a related cell surface receptor (CD95) 98. Once a ligand binds to its 
receptor, there is formation of a death-inducing signalling complex (DISC) that recruits 
initiator caspase-8 which upon activation, initiates activation of the executioner caspase, 
caspase-3 99. The intrinsic pathway is mediated by intrinsic stimuli which cause a decrease in 
mitochondrial membrane potential leading to a release of pro-apoptotic proteins such as 
cytochrome-c into the cytosol thereby triggering cell death 95,97. Cytochrome-c then binds to 
apoptotic protease activating factor 1 (Apaf-1) and activates the initiator caspase, caspase-9. 
Once activated, caspase-9 activates executioner caspase, caspase-3 99.  
An abnormal increase in FFAs modulates the extrinsic and intrinsic pathways of apoptosis.  
Unsaturated fats such as oleic acid, impart sensitivity to the death receptor-mediated apoptotic 
pathway by inducing CD95 and initiating the extrinsic pathway of apoptosis 98. Saturated FFAs 
such as palmitic and stearic acid, lead to c-jun N-terminal kinase (JNK) dependant activation 
of the intrinsic apoptosis pathway. This is related to mitochondrial oxidative stress and the 
interaction with members of the B-cell lymphoma 2 (Bcl-2) family of regulatory proteins 
bound to the mitochondrial membrane, including Bax (pro-apoptotic) and Bcl-2 (anti-
apoptotic) proteins 100.  
Impaired mitochondrial function is a central abnormality responsible for the progression of 
hepatic steatosis to steatohepatitis 101. Malhi et al., conducted a study that highlighted how 
hepatic lipoapoptosis was exhibited throughout the pathogenesis of NAFLD in several models 
of NAFLD, using monounsaturated and saturated fatty acids as a mode of induction in multiple 
hepatocyte cell lines and primary mouse hepatocytes 100. Equal cellular steatosis was observed 
regardless of the class of FFA used, however, the activation of apoptosis and JNK was greater 
during exposure to saturated FFAs as opposed to unsaturated FFAs 100. 
2.4 Current therapeutic intervention of NAFLD 
The past decades have provided us with evidence that shows how lipid droplet accumulation 
in the liver can decrease the efficiency of insulin and eventually full blown insulin resistance 
102. As ectopic lipid accumulation and insulin resistance occur there are complications in 
glucose and lipid homeostasis, which increase the risk for cardiovascular disease (CVD). 
Therefore, to understand the underlying mechanisms caused by the hepatic manifestation of 
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the metabolic syndrome, current therapeutic interventions that help alleviate the rise in CVD 
risk factors mainly caused by the pathogenesis of NAFLD will be discussed below.  
In insulin-resistant states such as NAFLD and NASH, marked depletion in circulating levels 
of adiponectin are observed 103. Several prospective studies have thus investigated how 
adiponectin levels change in the pathogenesis of NAFLD 104,105. Whereas a meta-analysis study 
showed that the progression from simple steatosis to NASH is resultant of a decrease in 
circulating adiponectin levels, and when NASH progresses to cirrhosis, an increase in 
adiponectin levels are observed 106. Furthermore, PPAR agonists have led to an increase in 
circulating adiponectin in conjunction with histological improvements in patients living with 
NASH. Treating patients with metformin for one year reduced aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) levels, and also increased serum adiponectin levels 
in patients that have developed NAFLD 107. Several studies have shown that TZDs; 
pioglitazone and rosiglitazone, improve adiponectin levels 17. Similarly, statins increase 
adiponectin levels and have been speculated to effectively manage NAFLD through its action 
on regulating dyslipidaemia 108. Therapeutic agents that have potential benefits to the liver, and 
insulin-sensitizing agents for T2DM are promising, although lipid-lowering medications are 
used for conventional indications instead of directly affecting NAFLD. The effect of direct 
replacement of adiponectin or other adipokines on NAFLD still needs to be investigated as 
there are no licensed pharmacological drugs that are currently approved by the U.S Food and 
Drug Administration 102. However, current recommendations for NAFLD therapy are limited 
to the treatment of individual characteristics of the metabolic syndrome such as type two 




Table 2.1 Summary of recommended pharmacotherapies for NAFLD and NASH 102. 
 
Anti-diabetic drugs include insulin sensitisers (biguanides; metformin and thiazolidinediones; 
pioglitazone), stimulating insulin secretagogues (sulfonylureas, glucagon-like peptide 1 (GLP-
1) receptor agonists (GLP-1 analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors), as well 
as suppressors of postprandial glucose uptake in the digestive tract (α-glucosidase inhibitors, 
acarbose) and inhibitors of renal reabsorption of glucose (sodium-glucose co-transporter-2 
(SGLT2), dapagliflozin) 109. Primary factors in selecting any of these glucose-lowering agents 
include efficacy in reducing hyperglycaemia, as seen with pioglitazone, and to reduce the 
progression of NAFLD. Alternatively, cholesterol-lowering drugs such as statins are also 
considered as possible therapeutic agents for NAFLD, through the inhibition of 3-hydroxy-3- 
methylglutaryl-CoA (HMG-CoA) reductase 10. However, the most extensively evaluated 
intervention for NAFLD are weight loss through lifestyle and dietary changes, as well as the 
use of antioxidants and natural medications 110. 
Pioglitazone is a synthetic ligand for PPARs and acts as a PPAR-γ agonist and insulin sensitiser 
111. Mechanistically, pioglitazone activates and translocates PPAR-γ to the nucleus which then 
forms a complex with the retinoid x receptor alpha, modulating several gluconeogenic genes 
in the liver. The transcription of the insulin-sensitive glucose transporter, GLUT4, is induced 
in adipose tissue 112,113; enhancing glycaemia, glucose transport and utilisation, as well as 
suppressing hepatic glucose production 114. Pioglitazone is classified as a weak ligand for 
PPAR-α, and as such reduces insulin resistance, suppresses inflammation and infers a role in 
increasing β-oxidation  whilst improving hepatic steatosis and non-alcoholic fatty liver disease 
115. Pioglitazone alters the transcription of genes, which influence lipid and carbohydrate 
metabolism whilst exhibiting anti-inflammatory effects in patients with NASH, due to its 
modulation of signalling pathways that are involved with intracellular pro-inflammation 17.  
Tabl 1: Sum ary of recommended pharmacotherapies for NAFLD and NASH
Drug Mode Of Action AASLD Guidance
(2017)
Side Effects
Pioglitazone PPAR-ϒ agonist, anti-diabetic drug
that helps restore insulin response thus 
lowering blood glucose levels





Metformin Biguanide, anti-diabetic drug, 
prevents production of glucose in the 
liver, lowering blood glucose
Not Recommended as treatment for 




Exenatide GLP-1 agonists, promoting the action 
of GLP-1 and insulin biosynthesis by 
pancreatic beta cells
Premature as a treatment for NASH Hypoglycemia
Kidney failure
Pancreatitis
Sitagliptin DPP-4 inhibitors, promoting the 
action of GLP-1 and insulin 
biosynthesis by pancreatic beta cells
Premature as a treatment for NASH Joint pain
Pancreatitis
Heart failure
Statins HMG-CoA reductase inhibitors, a 
class of cholesterol lowering drugs
Recommended for dyslipidemia, but 






Furthermore, pioglitazone improves NAFLD by suppressing steatohepatitis markers. However, 
side effects highlight the disadvantage of using pioglitazone, as it leads to significant weight 
gain 110. Despite this increase in weight, thiazolidinediones have the best evidence-based data 
for efficacy in NAFLD/NASH, but long-term adverse cardiovascular and other related side 
effects attributed to these drugs are a serious issue and are likely to prevent licensing of 
thiazolidinediones as treatment for NAFLD 102. 
2.5 Rooibos  
Given the need for therapeutics that offer long-term efficacy, with reduced side effects and 
cost, there is a growing interest for natural or plant-based therapies to help prevent or manage 
chronic metabolic conditions 27. Aspalathus linearis (Brum.f) Dahlg., also known as rooibos, 
is a South African fynbos shrub that belongs to the family Leguminosae and it is indigenous to 
the Cederberg region of the Western Cape Province, (Fig. 2.4). Rooibos is known for producing 
a mild-tasting herbal tea from freshly harvested leaves, which are sundried to oxidise (ferment) 
the harvested leaves and stalks for a richer taste and strong aroma. In South Africa, rooibos is 
ranked the most commonly consumed herbal tea as reported in 2011, by the South African 
Rooibos Council (SARC), with an estimated 10.9 million households actively consuming 
rooibos tea 23. The commercialised tea is mainly oxidised, producing a distinctive red colour, 
the tea is low in tannins, has no caffeine but is rich in unique bioactive polyphenolic compounds 
24. Compared to the traditional fermented rooibos tea, unfermented/green rooibos contains 
higher amounts of polyphenols, more specifically C-glucosyl dihydrochalcones, flavones and 





Figure 2.4 Greater Cederberg Biodiversity Corridor, production areas of Aspalathus linearis (Brum.f) 
Dahlg. (adopted from, Nordling 116). 
 
2.5.1 Biochemical characteristics and bioavailability of rooibos 
Several health benefits, that involve anti-inflammatory responses 117, glucose modulating 
118,119, anti-diabetic 120 and lipid-lowering effects 121, have been attributed to the use of rooibos 
as an alternative therapeutic 25. Rooibos contains some rare polyphenolic compounds and 
compounds of interest such as phenyl pyruvic acid glucoside (PPAG; Z-2-(b-D-
glucopyranosyloxy)-3-phenylpropenoic acid), as listed in Table 2.2 25,122. The major flavonoid 
found in rooibos is aspalathin, and to date aspalathin (a dihydrochalcone C-glucosyl) is 
uniquely found in Aspalathus species. During processing, oxidative changes to the phenolic 
composition of the plant forms part of the traditional fermented rooibos tea, which is rich in 
flavour, colour and aroma 23. In unfermented (green) rooibos the flavonoid content is higher. 
Extracts produced from unfermented/green rooibos, as per Table 2.2, is higher than the 




Table 2.2 Flavonoid content of unfermented rooibos extracts compared to fermented rooibos 
extracts 25,122. 
 
The absorption, distribution, metabolism and excretion (ADME bioavailability) determines the 
bioactivity of bioactive food compounds, as they should reach the site of action, to execute 
their health benefits 123. Plenty of factors limit or enhance the bioavailability of any compound, 
from ingestion, digestion in the digestive tract and its interactions with other dietary sources to 
name a few 124. An in vitro study using a Caco-2 monolayer cell model demonstrated, that the 
absorption of aspalathin improved when present in an unfermented green rooibos extract as 
opposed to a pure aspalathin compound 125. The study critically highlighted how the other plant 
components in the extract may assist in the transport of aspalathin across the membrane.  
In an in vivo study by Kreuz et al., pigs which were fed an aspalathin-enriched, unfermented 
“green” rooibos extract equalling, 157–167 mg/kg body weight per day for eleven days, 
reported no aspalathin and metabolites detected in the plasma of the treated animals 126. Several 
metabolites, aglycones of aspalathin, dihydro-(iso)orientin and aspalathin conjugated with a 
methyl group and/or glucuronic acid were found in the pigs’ urine, suggesting that the 
absorption of aspalathin could have been attributed to the liberation of the aglycones by colonic 
microflora 126. The study by Kreuz et al., along with a study on non-human primates 127, also 
revealed that with a single dose of the aspalathin-enriched unfermented “green” rooibos extract 
about three times higher, trace amounts of aspalathin were detected in the blood plasma of the 
treated animals 126. 
  
Table 2: Flavonoid content of unfermented rooibos extracts compared to fermented rooibos extracts.
Extract (g/100g)
COMPOUND UNFERMENTED FERMENTED














Phenylpropenoic acid glucoside PPAG 0,27 0,57
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2.5.2 Hepatoprotective effects 
Patients presenting with glucose intolerance and dyslipidaemia are progressively considering 
natural products as an alternative or adjunctive therapy as opposed to conventional medications 
due to their perceived health benefits and efficacy 128. Several of these natural products contain 
phenolic compounds such as flavonoids known to be largely responsible for the biological 
activity, including beneficial effects on glucose and lipid metabolism 129. Within this context, 
several studies have alluded to the glucose and lipid modulating effects of rooibos 130, as 
aspalathin was demonstrated to stimulate insulin release from pancreatic beta cells and a 
subsequent increase in glucose uptake in muscle tissues, thus benefiting glucose homeostasis 
in various models of T2DM 25. In addition, rooibos has also been shown to have LDL-C 
lowering 131, and cardioprotective effects 130. A study by Patel et al., demonstrated, the safety 
and pharmacological effects of an aspalathin-rich unfermented “green” rooibos extract in 
combination with pioglitazone and atorvastatin in vivo using a Wistar rat model 132. The in vivo 
study showed a significant pharmacokinetic interaction, where “GRT” moderately inhibits 
cytochrome P450-3A4 (CYP3A4) activity, affecting the bioavailability of drugs metabolised 
by the CYP iso-enzyme 132. 
Literature has demonstrated the association between the consumption of foods rich in 
flavonoids and cellular damage, through radical scavenging of ROS and enzymatic processes 
responsible for free radical production 133. A study conducted by Ajuwon et al., investigated 
the effects of a fermented rooibos extract on a Wistar rat model and assessed the hepatic 
markers of oxidative stress, as well as the release of pro-inflammatory cytokines in 
lipopolysaccharide (LPS)-induced liver injury 22. LPS treatment significantly increased serum 
levels of ALT, AST and LDH, resulting in the induction of liver injury, attributed to toxic 
mediators produced by activated macrophages 134. The study concluded that treatment with a 
fermented rooibos extract attenuated LPS-induced liver injury, by suppressing the formation 
of pro-inflammatory cytokines and modulating oxidative stress levels 22. This is interesting, 
however the efficacy of an aspalathin-rich unfermented “green” rooibos extract is yet to be 





The use of rooibos as a potential therapeutic will not only benefit the local market because the 
herbal tea is indigenous to South Africa but will also have a huge impact on markets globally. 
This is because the United Kingdom together with Germany, the Netherlands, Japan, and the 
United States of America are some of the top importers of rooibos, representing more than 80% 
of the export market (data supplied by South African Rooibos Council, 2013) 135. 
2.6 Models used to study the pathogenesis of non-alcoholic fatty liver disease 
To study the pathogenesis of NAFLD, researchers have used various animal models 
incorporating pathological patterns and histological alterations found in the different stages of 
the disease in humans. Rodents have been the leading in vivo model used in biomedical 
research, with genetically modified and dietary induced rodent models employed to mimic the 
pathogenesis of the disease 136. Other animal models for example, Ossabaw pigs and primates 
are larger animal models and are much related to humans than rodents but are also expensive 
options to use in a laboratory 137. 
In vitro models for NAFLD are considered an alternative approach to elucidate the molecular 
mechanisms involved in the progression of the disease. Previously, researchers were 
investigating signalling cascades and mechanisms of action using in vivo models of NAFLD 
and confirmed the findings through clinical studies 138. However, recent studies have employed 
the use of primary cell cultures and immortalised cell lines to widely improve in vitro models 
of NAFLD 139. Human or model organism cells are cultured in various conditions to induce 
pathological patterns observed in humans suffering from the disease. Various culturing 
techniques are utilised such as mono-culture, co-culture and three-dimensional cell culture 
models, where the complex architecture, interaction and physiological setting of the hepatic 




Figure 2.5 Various in vitro models of NAFLD (adapted from, Kanuri and Bergheim 137). 
 
The most abundant dietary FFAs are unsaturated oleic acid as well as saturated palmitic acid 
140. These free fatty acids have been identified in liver steatosis, and literature has confirmed 
steatosis induction using both FFA’s in vitro and in vivo using various liver cell lines and rodent 
models 141,142. Palmitic acid has shown to be cytotoxic at concentrations higher than 0,75 mM, 
thus NAFLD experimental induction methods would ideally lean towards the use of oleic acid 
to avoid cytotoxicity 143. Genetic rodent models serve well as in vivo models of NAFLD due 
to the low variability caused by dietary models.  
The study was therefore aimed at investigating the potential of a aspalathin-rich green rooibos 
extract (Afriplex GRT) as a therapeutic intervention to protect against hepatic oxidative stress, 
inflammation and apoptosis in experimentally induced cell (in vitro) and animal (in vivo) 
models of NAFLD.  
The objectives of the study were (i) to establish an in vitro model of steatosis using C3A cells 
treated with oleic acid, (ii) to treat the oleic acid-induced cells with pioglitazone and Afriplex 
GRT as mono-therapies and in combination, (iii) to perform histological analysis of mouse 
liver sections obtained from a previous study to confirm hepatic steatosis and assess the effects 
of treatment, as well as (iv) an expression analysis of target genes and proteins using qRT-PCR 





Interplay between various cell lines
Primary or Immortalized cells
Organoids from 




3.1 Experimental Design: 
In vitro and in vivo models of NAFLD: 
An immortalised liver cell line, a derivative of HepG2 (HepG2/C3A) hepatocytes, was utilised 
in the in vitro study as a representative liver cell line to experimentally induce hepatic steatosis 
using oleic acid to assess the potential therapeutic intervention by treating with Afriplex GRT, 
(Figure 3.1).  
The in vivo study used liver tissue samples from leptin receptor-deficient non-diabetic db+ 
(lean) and obese diabetic db/db (obese) male mice from a previous study. The db/db mice are 
leptin receptor-deficient (Leprdb) and have persistent hyperphagia, become obese and 
spontaneously develop diabetes that is associated with hepatic steatosis. This provided a rodent 
model that mimicked NAFLD in human patients, (Figure 3.2).  
3.2 Cell culture: 
Sub-culture of C3A liver cells: 
Vials containing C3A liver cells (ATCC CRL-10741) which were stored at -196 °C, were 
thawed at room temperature in a laminar flow hood (Labtech™, Ortenberg, Germany) at 23 
°C with a windspeed of 0.53 m/s, to ensure sterility for subsequent culturing in 17 mL of 
Eagle’s essential minimal medium (EMEM) that was pre-warmed to 37 °C and supplemented 
with non-essential amino acids, sodium pyruvate (1 mM), foetal bovine serum (FBS) (10%), 
L-glutamine (1%) and glucose (19.5 mM). Inoculation of the cell suspension into a 75 cm2 cell 
culture flask was performed. The flask was then incubated at 37 °C and humidified with 5% 
CO2 overnight. Passage numbers were recorded (restricted to below 30 passages) to avoid 
phenotypic drift from the number of times the cells were trypsinised and reseeded. The medium 
was refreshed (every second day) until the cells reached the targeted 80 % confluency to resume 
the experimentation. 
The cells were sub-cultured using the standardised protocol until they reach 75-80% confluence 
to be used for further experimentation. The spent media was aspirated, and the remaining cells 
were washed with 8 mL of [1x] phosphate-buffered saline (PBS). To retrieve the cells, 3 mL 
of trypsin was added to each 75 cm2 flask, and the cells incubated, as above, for 3-7 min. 
Standardised cell culture growth medium (7 mL) was added to the cells to inactivate trypsin 
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and a single cell suspension was obtained by pipetting the cell suspension with a 10 mL 
serological pipette. A 15 mL centrifuge tube was then used to centrifuge the transferred cell 
suspension at 800 x g using SL16R centrifuge (ThermoFischer Scientific™, Massachusetts, 
USA) for 5 min. Depending on the size of the cell pellet, the pellet was then re-suspended in 5-
10 mL cell culture growth medium and 0.5 mL of the suspension transferred into a centrifuge 
tube (2 mL) for cell counting. 
Counting of the cells was done by pipetting the cell suspension (10 μL) into a centrifuge tube 
(2 mL), which contained 10 μL of trypan blue solution at 0.4% and mixed by pipetting up and 
down. The mixture (10 μL) was then pipetted onto a haemocytometer and live cells were 
manually counted in each quadrant using phase contrast on an inverted light microscope at 10x 
magnification (Olympus CK x31, Tokyo, Japan). The 5-10 mL cell suspension was 
subsequently seeded using a standardised cell density for C3A cells (10 x 105, 1.0 x 105 cells 
per well for 96 and 24/6 well plates, respectively), as previously determined by Mazibuko 144. 
For quantitation of cell viability and the determination of lipid accumulation, 96 well cell 
culture plates were used. For mitochondrial depolarisation assays, 24 well cell culture plates 
were used and finally, 6 well cell culture plates were used for cell harvesting for genomic and 
proteomic analysis.  
3.2.1 Treatment conditions: 
Induction and anti-steatosis treatment of HepG2/C3A liver cells: 
HepG2/C3A liver cells were sub-cultured for three consecutive passages before treatment with 
an optimised concentration of oleic acid [1 mM] (Sigma-Aldrich, St. Louis, USA) for 24 h, to 
induce hepatic steatosis, as previously reported by Alkhatatbeh et al. 145. A 24 h treatment 
assessment on the anti-steatosis effects of Afriplex GRT and/or pioglitazone was determined 
through the use of monotherapies and co-treatments, at various concentrations, following a 24 
h steatosis induction period.  
Stock concentrations at [100, 10 and 1 mg/mL] of Afriplex GRT extract were prepared by 
weighing 10 mg of the pure extract and dissolving it in 0.1 mL of 100% DMSO and serial 
diluting the solution (1:100) in supplemented EMEM growth media to obtain the desired stock 
concentrations. A stock concentration at [30 mM] of pioglitazone (Sigma-Aldrich, St. Louis, 
USA) was prepared by weighing [11.787 mg] of the pure compound and dissolving it in 1 mL 
of 100% DMSO. Induction media was prepared fresh each day and the cells were grouped and 
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induced as per table 3.1 below, using oleic acid for 24 h. Treatment media for the various 
concentrations was prepared fresh the next day and the treatments were grouped as per table 
3.1 below; including a 0.1% DMSO vehicle control as the stock treatments were dissolved in 
100% DMSO and finally obtained a final concentration of 0.1% DMSO as well as the desired 
treatment concentrations. 




Normal Control None None 
Induced Control 1 mM None 
DMSO Vehicle Control 1 mM 0.1% 
Pioglitazone 1 mM 30 μM  
Afriplex GRT 1 mM 1 μg/mL 
1 mM 10 μg/mL 
1 mM 100 μg/mL 
Pioglitazone + Afriplex GRT 1 mM 30 μM + 1 μg/mL 
1 mM 30 μM + 10 μg/mL 
1 mM 30 μM + 100 μg/mL 
 
 








Protein Extraction and 
Expression Analysis (Western Blot) 





















3.3 In vitro biochemical assays, staining techniques and harvesting:  
3.3.1 Cell viability testing of C3A liver cells: 
In vitro mitochondrial dehydrogenase activity: 
The mitochondrial succinate dehydrogenase activity of the cells exposed to steatosis induction 
and anti-steatosis treatment was analysed using a 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium (MTT) assay. The colorimetric assay measured the cell metabolic activity 
following induction and treatment of the cells. The MTT assay determines the relative viability 
of the cells by assessing the cell metabolic activity in each treatment condition along with its 
controls. The assay is based on the ability of NADPH-dependent cellular oxidoreductase 
enzymes to reduce the MTT dye to a purple formazan 146.  
Therefore, following treatment of the C3A liver cells an MTT assay was conducted on the 96 
well cell culture plate by incubating the treated cells with an MTT reagent (2 mg/mL) at 37 °C 
for 30 min. After incubation, 200 μL DMSO and 25 μL Sorenson’s buffer was added into each 
well, and the plate was kept at room temperature, and wrapped in aluminium foil to block out 
light. The plate was subsequently read using a plate reader ELx800 (BioTek®, Winooski, VT, 
USA) at an absorbance reading of 570 nm. 
3.3.2 Lipid analysis:  
Lipid accumulation assay of C3A liver cells: 
Following steatosis induction with oleic acid and the anti-steatosis effects of Afriplex GRT and 
pioglitazone, free fatty acids within the cultured cells and the lipid content were evaluated using 
an oil red O (ORO) based colorimetric and cell staining assay. Oil red O is described as a 
hydrophobic dye that is substantially more soluble in neutral triglycerides and lipids than its 
solvent alcohol 147. 
Briefly, following treatment, the C3A liver cells were fixed using 10% formalin onto the 96 
well tissue culture plates for 15 min at room temperature. Once fixed the cells were rinsed with 
100 μL PBS to get rid of formalin. A 0.7% working solution of ORO was then added to the 
cells and were incubated for 30 min at room temperature. The ORO stain was aspirated, and 
the stained cells were rinsed several times with distilled water followed by visualisation at 20x 
and 40x magnification under an inverted light microscope (Olympus CK x31, Tokyo, Japan). 
After visualisation, the distilled water was aspirated, and absolute isopropanol was added to 
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the cells to extract the dye from the stained fatty acids. The extracted stain was therefore 
transferred into a fresh 96 well assay plate and the absorbance (490 nm) was read on a plate 
reader ELx800 (BioTek®, Winooski, VT, USA).  
After extraction of ORO, the cells were rinsed with 70% ethanol and the ethanol was then 
aspirated.  The nuclei of the cells were subsequently stained with 0.5% crystal violet (CV) 
working solution and incubated for 5 min at room temperature, to account for the viability of 
the cells during the experiment. The CV stain was then aspirated completely and after rinsing 
the cells a few times with PBS, 70% ethanol was added into each well and the CV stain was 
extracted from the cells. The CV stain was then transferred to a fresh 96 well assay plate, and 
the CV absorbance (570 nm) intensity was read on a plate reader ELx800 (BioTek®, Winooski, 
VT, USA). 
3.3.3 Mitochondrial membrane potential: 
The 5, 5', 6, 6'-Tetrachloro-1, 1', 3, 3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) is a 
lipophilic cationic fluorescent dye, which through mitochondrial membrane potential, serves 
as an indicator of cell health. The JC-1 dye fluoresces green (λex 520 nm) in its monomeric 
form when exposed to unhealthy cells due to a low membrane potential and in healthy cells the 
JC-1 dye fluoresces red (λem 596 nm) by the formation of J-aggregates due to a high membrane 
potential. Based on the green to red fluorescence ratio of the dye in the mitochondria an 
assessment of mitochondrial depolarisation can be considered as the higher the green/red 
fluorescence ratio the higher the depolarisation of the mitochondrial membrane, as previously 
reported 148.  
Thus, the anti-steatosis potential of Afriplex GRT and pioglitazone on oleic acid-induced 
steatosis were determined by assessing the mitochondrial membrane potential using a JC-1 
stain (cat. no.: T3168; Sigma, Stanheim, Germany) 149. Following the 24 h treatment, the media 
was discarded, and cells washed with 500 μL PBS and stained with 500 μL of 2 μM JC-1 stain 
and the cells incubated at 37 °C for 30 min. Following incubation the cells were washed once 
again with 500 μL PBS and mitochondrial membrane potential was imaged using a Nikon 
Eclipse Ti/S Fluorescence Microscope with digital camera (Nikon, Minato City, Tokyo, Japan) 
at 200x magnification 149. The intensity of the red fluorescence was then quantified using the 
ImageJ32 software application (imagej.nih.gov/ij/list.html) through densitometric analysis. 
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3.3.4 Cell harvesting: 
Following a 24 h stress induction and a further 24 h of treatment with Afriplex GRT and 
pioglitazone in 6-well cell culture plates (as shown in section 3.2 above), cell culture medium 
was aspirated, and the attached cells were washed with 1 mL ice-cold PBS. After the wash 
step, 0.3 mL Buffer RLT (Qiagen™, Hilden, Germany) [for mRNA extraction] or 0.3 mL 
Invitrogen™ Tissue Extraction Reagent I (ThermoFischer Scientific™, Massachusetts, USA) 
[for protein extraction] was added into each well and the cells were detached from the tissue 
culture plates using a cell scraper. The cells were then pooled per treatment sample to make up 
a total volume of 0.9 mL of each cell suspension. The collected samples per treatment were 
transferred from the plates into 2 mL centrifuge tubes and kept on ice throughout the sample 
harvest period. 
3.4 Animal handling:  
Ethical approval and growth parameters: 
The study made use of 40 C57BL/6 Lepr db/db and db/+ mice from Jacksons laboratory, which 
were housed at the SAMRC Primate Unit and Delft Animal Centre (PUDAC). The SAMRC-
Ethics Committee for Research in Animals (SAMRC-ERCA) and the University of Zululand 
Committee on Animal Research and Ethics (UZREC), approved the animal study, with 
reference numbers (SAMRC-ERCA REF.05/17) and (UZREC 171110-030) respectively, see 
appendices (subsection 9.1 and 9.2). Additional ethical clearance was requested and granted 
from Stellenbosch University (ACU-2020-14382) (subsection 9.3 of appendix). 
The mice model presents with obesity traits at four weeks of age, as the mice actively express 
the (Leprdb) mutation. These mice were housed in pairs, with free access to food (standard 
chow diet) and water, in a relative humidity of 50%, controlled temperature of 23-24 oC and 
12 h light and dark cycles. For six weeks, the mice were acclimatised to the experimental 
environment, with body weights assessed weekly. 
The mice were then randomised into four db/db treatment groups (n = 8 per group), with the 
lean db/+ (n = 8 per group) littermates included as controls. Food intake data were recorded 
weekly by weighing the food given to the mice in the feeder and weighing the food left and the 
spillage to work out the food consumed. Body weights were also measured weekly throughout 
the ten-week treatment period.  
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3.4.1 Treatment conditions and tissue harvesting: 
Anti-diabetes treatment of genetically induced diabetic mice: 
The mice were randomly grouped into Control (db/+), Untreated (db/db), Pioglitazone [15 
mg/kg] treated (db/db), GRT 1 [74 mg/kg] treated (db/db) and GRT 2 [740 mg/kg] treated 
(db/db) groups, where the animals were given treatment mixed with powdered standard chow 
diet daily for ten weeks. The Afriplex GRT extract was used for treatments (GRT 1 and GRT 
2). The control and untreated groups were fed the same food equivalent but with treatment 
excluded. Daily treatment dosages were administered in proportion to the average daily food 
intake. The treatment doses of pioglitazone and Afriplex GRT were both selected based on 
previous animal studies 120,150 with the mouse equivalent dosages converted using the 
conversion formula described by Reagan-Shaw et al. 151. 
 
Figure 3.2 In vivo db/db mouse study outline and study design. 
 
Animal terminations and tissue collection: 
After 10 weeks of treatment, the mice were anaesthetised with 2% fluothane and 98% oxygen 
gas inhalation. Deep anaesthesia was tested by the pinch of the toe, and once established, 
animals were euthanised by exsanguination with blood drawn from the vena cava and the liver 
collected and weighed. The harvested organs were either snap-frozen (for protein expression), 
db+ and db/db mice
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preserved in RNAlater® (Applied Biosystems, CA, USA) [for mRNA extraction] or fixed 
overnight in 10% phosphate-buffered formalin, pH 7.4 [for histology]. 
3.5 Biochemical assays and staining techniques:  
Haematoxylin and Eosin staining of liver sections: 
A histological examination of the harvested liver tissue samples was performed to assess 
abnormalities related to hepatic steatosis and NAFLD, across the treatment groups. Liver 
samples were fixed overnight in 10% phosphate-buffered formalin (pH 7.4), thereafter 
processed on a TP 1020 automatic tissue processor (Leica, Wetzlar, Germany) through 
increasing concentrations of ethanol (70% EtOH for 1.5 h, 90% EtOH for 2 h and absolute 
EtOH for 3 h). The tissue was also processed through xylene before being impregnated with 
heated paraffin wax. Once processed, the tissue embedded in paraffin wax was cut in 5 μm 
sections using a RM 2125 RTS rotary microtome (Leica, Wetzlar, Germany).  
The cut sections were then floated out in a water bath (± 40 °C) and mounted onto 3-
aminopropyltriethoxysilane (APES) coated slides. The slides were heated at 60 °C for 45 min, 
adhering the sections to the melted wax. Before rehydrating the sections with decreasing 
concentrations of ethanol (absolute and 95%), the slides were dewaxed with two ten-minute 
changes of xylene. The rehydrated and dewaxed slides were rinsed with distilled water and 
subsequently stained with haematoxylin (Mayer’s) stain for 12 min. The stained slides were 
washed with distilled water and then counterstained with 1% eosin stain (aqueous solution) for 
2 min. Stained slides were dehydrated with increasing ethanol concentrations (95% and 
absolute) and cleaned with xylene, prior to mounting. The slides were mounted with Entellan® 
mounting medium and 24 x 40 mm coverslips were used. Slides were left to air dry at room 
temperature and the slides were visualised and images captured under a Nikon Eclipse Ti/S 
Inverted Microscope with digital camera (Nikon, Minato City, Tokyo, Japan) at 200x 
magnification. 
The mounted liver sections, were assessed for their hepatic steatosis severity using the NAFLD 
severity scoring method defined in a study by Trak-Smayra et al. 152. The method scores the 
intensity, distribution and lipid content accumulated in the mice liver lobules. Thus, the 
intensity of hepatic steatosis was assessed as the percentage of hepatocytes which contained 
lipid vacuoles analysed at 200x magnification in ten randomly selected non-overlapping fields. 
The zonal distribution within the lobules was also used to further score the lipid accumulation 
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in the liver sections. The size of the lipid vacuoles identified in the hepatocytes classifies the 
type of steatosis observed in the liver sections. 
Blood glucose and oral glucose tolerance test: 
Fasted blood glucose levels were measured weekly using OneTouch Select® glucometer, by 
loading a blood sample obtained from a tail prick. A week prior to terminations, the animals 
were subjected to an oral glucose tolerance test (OGTT). The mice were fasted for 16 h and a 
baseline glucose level was determined, thereafter the mice were given 1 g/kg glucose via oral 
gavage. The blood glucose levels were measured from a tail prick at various time points (0, 15, 
30, 60 and 120 min). The area under the curve (AUC) was subsequently calculated with the 
trapezoidal rule on GraphPad Prism version 7.00 for Macintosh. 
3.6 mRNA extraction and quantification from cells and liver tissue:  
Cell lysates were prepared from harvested C3A cells on ice using Buffer RLT (Qiagen™, 
Hilden, Germany) and the total mRNA was extracted from the harvested C3A liver cells using 
an RNeasy mini kit (ThermoFischer Scientific™, Massachusetts, USA). The extracted mRNA 
was subsequently used for cDNA synthesis for use in qRT-PCR analysis, with the aim to detect 
genes involved in; insulin signalling (IRS1) and glucose transport (GLUT2), lipid and glucose 
metabolism (AMPK-α), (PPAR-γ), (PPAR-α), Fatty acid synthase (FASN), Glucose-6-
phosphatase (G6PC), Phosphoenolpyruvate carboxykinase 1 (PCK1), (SREBF1) and 
carbohydrate-response element-binding protein (CHREBP) and oxidative stress response, 
Glutathione peroxidase 2 (GPX2) and superoxide dismutase 2 (SOD2) respectively. 
Liver tissue lysates were prepared from 50 mg of harvested liver tissue on ice using Buffer 
RLT (Qiagen™, Hilden, Germany) and the total mRNA was extracted from the harvested liver 
tissue using a RNeasy mini kit (ThermoFischer Scientific™, Massachusetts, USA). mRNA was 
subsequently converted into cDNA for qRT-PCR analysis, with the aim to detect genes 
involved in; apoptosis (Casp3), insulin signalling (Irs1), glucose transport (Glut2), lipid and 
glucose metabolism (Ppar-γ, Ppar-α, Fasn, Srebf1 and Chrebp) and oxidative stress response 
(Sod2) respectively. 
Following cell or tissue harvesting, a stainless-steel bead (Qiagen™, Hilden, Germany) was 
added to each 2 mL centrifuge tube containing the cell suspension or liver tissue. The samples 
were then homogenised using a TissueLyser (Qiagen™, Hilden, Germany) at 25 Hz for sixty 
seconds, and this was repeated four or five times for C3A liver cells, with 1 min intervals on 
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ice. The homogenised suspension was then centrifuged at 15000 x g for 15 min at 4 °C. The 
supernatant was carefully removed and transferred to a 2 mL Eppendorf tube, where one 
volume of 50 % ethanol was added to the lysate and mixed by pipetting up and down. 
Thereafter, 550 µL of the homogenate sample was transferred to a RNeasy spin column placed 
in a 2 mL collection tube which is supplied by the manufacturer in the kit. The samples were 
then centrifuged at 15000 x g for 15 sec at room temperature, and the flow-through was 
discarded. 
The spin columns were centrifuged at 15000 x g for 15 sec at room temperature, with 700 µL 
of the RW1 buffer, and the flow-through was discarded. Thereafter, 500 µL of the RPE buffer 
was added to the spin columns, which were then centrifuged at 15000 x g for 15 sec at room 
temperature with the flow-through discarded and the step repeated. The spin columns were 
placed in fresh 2 mL centrifuge tubes and then centrifuged at full speed for one minute. 
Following centrifugation, the spin columns were placed in fresh 1.5 mL centrifuge tubes, which 
were supplied by the manufacturer. RNase-free water (50 µL) was added directly to the spin 
column membrane, which were then left to stand for a minute and then centrifuged at 15000 x 
g for one minute to elute the RNA.  
The eluted RNA samples were thus placed on ice for the quantification step using the Nanodrop 
ND-100 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). The samples 
were measured by blanking initially with 1 µL of the RNase-free water, thereafter 1 µL of the 
sample was loaded onto the pedestal and the absorbance was measured. The purity of the RNA 
samples was determined from the 260/280 nm ratio reading of the Nanodrop system. The value 
ranging from 1.8 to 2 suggested a pure RNA sample measured in duplicates to account for 
pipetting errors. 
3.6.1 DNAse treatment and cDNA synthesis: 
Genomic DNA contamination was eliminated from RNA samples by DNase treatment using 
the Turbo DNase kit according to the manufacturer’s protocol (ThermoFischer Scientific™, 
Massachusetts, USA). Briefly, RNase-free water was added to 20 µg of RNA, to a final volume 
of 50 µL. Thereafter 5 µL of DNase buffer and 1 µL of DNase were added to the RNA samples 
and incubated at 37 °C for 30 min. An additional 1 µL of DNase was added to the RNA and 
incubated at 37 °C for another 30 min. Thereafter, 10 µL of the DNase Inactivation Reagent 
was added to the RNA samples. The samples were then placed in an orbital shaker for 5 min 
at room temperature and then centrifuged at 15000 x g for a minute and a half. The RNA was 
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transferred to a fresh tube and the RNA concentrations were read using NanoDrop™ OneC 
spectrophotometer (ThermoFischer Scientific™, Massachusetts, USA).  
Nuclease-free water was added to the DNase treated samples to a volume of 10 μL. Total RNA 
(2 μg) was thereafter reverse transcribed into a single‐stranded complementary DNA (cDNA) 
using the High-Capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, 
USA), according to the manufacturer’s instructions (Cat. no.: 4368814). A PCR reaction mix 
was prepared containing 12.5 μL SYBR Green master mix, 1 μL ActB primers (10 μM) and 
9.5 μL nuclease-free water to a total volume of 24 μL per reaction. To test the cDNA for 
genomic DNA contamination, 1 μL cDNA was pipetted into a 96-well PCR plate and 24 μL of 
the PCR reaction mix was added to a total reaction volume of 25 μL, per well. The plate 
containing the reaction mix with cDNA was then mix and centrifuged on a benchtop centrifuge 
and the reaction was run at standard PCR conditions (Table 3.2) using ABI 7500 Sequence 
Detection System (Applied Biosystems, Foster City, CA, USA). 
Table 3.2 Thermal Cycler Running Conditions. 
Stage Cycle Repetitions Temperature  Time 
1 (Hold) 1 50.0 °C 02:00 min 
2 (Hold) 1 95.0 °C 10:00 min 
3 (Amplification) 40 95.0 °C 00:15 min 
  60.0 °C 01:00 min 
 
3.6.2 qRT-PCR Analysis: 
TaqMan® gene expression assay probes (ThermoFischer Scientific™, Massachusetts, USA) 
were used to assess the mRNA expression of both in vitro (Table 3.3) and in vivo (Table 3.4) 
studies. A PCR master mix was prepared by adding 5 μL TaqMan® universal master mix to 
0.5 μL of the TaqMan® gene expression assay probe and 3.5 μL nuclease-free water. The 
made-up PCR master mix was pipetted into a 96-well PCR plate (9 μL per well) with 1 μL 
cDNA per well.  
Treatment plates were measured using the standard curve method, a 10-fold serial dilution was 
constructed using a combination of control and treatment samples. Housekeeping genes were 
used to normalise the relative expression across the various genes tested. β-Actin was used to 
normalise samples of the in vitro model and Hprt was used to normalise the samples of the in 
vivo model, as β-Actin was regulated in the mouse liver samples. The fold change was 
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calculated using the equation: fold change	=	( treatment	-	normal control
normal control
) and the treatments were 
compared to the control which was set at 1. Real time qPCR was analysed in duplicate and 
once prepared the plates were then shaken and centrifuged on a benchtop centrifuge and the 
reaction was run at standard PCR conditions (Table 3.2) using ABI 7500 Real-Time PCR 
System, (Applied Biosystems, Foster City, CA, USA). 





Target species: Gene name: 
PRKAA1 Hs01562307_mH Human AMPK-α 
MLXIPL Hs00975714_m1 Human ChREBP 
FASN Hs01005622_m1 Human FASN 
G6PC Hs02802676_m1 Human G6PC 
SLC2A2 Hs01096906_g1 Human GLUT2 
GPX2 Hs01591589_m1 Human GPX2 
IRS1 Hs00178563_m1 Human IRS-1 
PCK1 Hs00159918_m1 Human PCK1 
PPARA Hs00947536_m1 Human PPAR-α 
PPARG Hs01115513_m1 Human PPAR-$ 
SOD2 Hs00167309_m1 Human SOD2 
SREBF1 Hs02561944_s1 Human SREBF1 
ACTB Hs03023943_g1 Human β-ACTIN (Housekeeping) 
 





Target species: Gene name: 
Mlxipl Mm02342723_m1 Mouse Chrebp 
Casp3 Mm01195085_m1 Mouse Caspase-3 
Fasn Mm00662319_m1 Mouse Fasn 
Slc2a2 Mm00446229_m1 Mouse Glut2 
Irs1 Mm01278327_m1 Mouse Irs-1 
Ppara Mm00440939_m1 Mouse Ppar-α 
Pparg Mm00440940_m1 Mouse Ppar-$ 
Sod2 Mm01313000_m1 Mouse Sod2 
Srebf1 Mm00550338_m1 Mouse Srebf1 




3.7 Protein expression and quantification:  
Cell lysates were prepared from harvested C3A cells on ice using Invitrogen™ Tissue 
Extraction Reagent I (ThermoFischer Scientific™, Massachusetts, USA). The total protein was 
harvested from the lysates and Western blot analysis was then conducted using methods 
previously described by Johnson et al. 153. Protein concentrations were determined using a 
Pierce™ BCA Protein Assay Kit (ThermoFischer Scientific™, Massachusetts, USA) and equal 
amounts of proteins were separated on a 12% SDS PAGE and electro-transferred onto 
polyvinylidene fluoride (PVDF) membrane, to detect proteins involved in; insulin signalling 
(IRS1 and PI3K), lipid and glucose metabolism (AKT, AMPK-α, PPAR-γ and MLYCD) 
oxidative stress (GSTZ1), inflammatory response (TNF-α) and apoptotic pathways (Caspase-
3), respectively. 
Liver tissue lysates were prepared from 50 mg of harvested liver tissue kept on ice using 
Invitrogen™ Tissue Extraction Reagent I (ThermoFischer Scientific™, Massachusetts, USA). 
Western blot analysis was then carried out according to established methods at the SAMRC 
(South African Medical Research Council) BRIP (Biomedical Research and Innovations 
Platform) 153. Protein concentrations were determined using a Pierce™ BCA Protein Assay Kit 
(ThermoFischer Scientific™, Massachusetts, USA) and equal amounts of proteins were 
separated on a 12% SDS PAGE and electro-transferred onto polyvinylidene fluoride (PVDF) 
membrane, to detect proteins involved in; lipid and glucose metabolism (AKT, AMPK-α, 
PPAR-α and MLYCD) oxidative stress (GSTZ1), inflammatory response (TNF-α) and 
apoptotic pathways (Caspase-3), respectively. 
Following cell or tissue harvesting, a stainless-steel bead (Qiagen™, Hilden, Germany) was 
added to each 2 mL centrifuge tube containing the cell suspension or liver tissue. The samples 
were then homogenised using TissueLyser (Qiagen™, Hilden, Germany) at 25 Hz for sixty 
seconds, this was repeated 5-6 times, with 1 min intervals on ice. The homogenised samples 
were then centrifuged at 15000 x g for 15 min at 4 °C using. The supernatant containing the 
total protein was carefully removed and transferred into 1.5 mL centrifuge tube for storage at 
-20 °C. 
Total protein concentrations were determined using Pierce™ BCA Protein Assay kit 
(ThermoFischer Scientific™, Massachusetts, USA). The BCA working reagent was prepared 
by adding 50 parts of solution A with 1 part of solution B, as per manufacturer’s instructions. 
A 10 μL volume of BSA standards (0.125 μg/mL to 2 μg/mL) was pipetted into a 96-well flat-
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bottom assay plate. The same volume of the experimental samples was pipetted into the assay 
plate and 200 μL of the working reagent was added to each well containing 10 μL of the sample 
or standard. The assay plate containing the samples and reagents was placed onto a plate shaker 
and generously mixed by shaking for 10 sec. The assay plate was then incubated at 37 °C for 
30 min before the absorbances (570 nm) of the samples were read on a plate reader ELx800 
(BioTek®, Winooski, VT, USA). The absorbance readings from the BCA assay was used to 
calculate the concentrations of the experimental samples by extrapolating the data from the 
standard curve. 
3.7.1 Casting and running sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE): 
The protein samples were separated using a 12% SDS PAGE prepared using TGX Stain-free 
FastCast Acrylamide kit (Bio-Rad, Hercules, USA). The gels were prepared based on the 
number of gels needed, in a glass beaker. The resolver gel was poured into 1.5 mm Bio-Rad 
(Bio-Rad, Hercules, USA) spacer plates, leaving 1.5 cm for the stacking gel, and the gel was 
allowed to polymerise over 30 min. The stacking gel was then prepared and poured over the 
polymerised resolver gel and based on the number of samples, an appropriate well-forming 
comb was added without trapping any bubbles, while the gel polymerised over 30 min.  
Once the gels have set the glass plates were removed from the casting tray and were installed 
into the mini cell buffer dam. A 1x running buffer was made up and poured into the inner 
chamber until an overflow was reached. Protein samples were allowed to thaw on ice and were 
then diluted (1:1) with 2x Laemmli sample buffer 154. The samples were heated at 95 °C for 5 
min on the AccuBlock digital dry bath (Labnet™, Edison, NJ, USA), then immediately put back 
on ice.  
A Precision Plus Protein All Blue ladder (5 μL) and the protein samples (30 μg) were loaded 
into each well of the 12% polyacrylamide gel for a total protein profiling gel, which was then 
electrophoresed at 150 V for 1 h. Following electrophoresis, the total protein profiling gels 
were then stained in 0.1% (w/v) Coomassie Brilliant Blue stain overnight before destaining in 
a destaining solution and an image was then processed on a ChemiDoc MP (Bio-Rad, Hercules, 
USA). The same methodology was followed when running gels for Western Blot analysis, 




3.7.2 PVDF membrane equilibration and protein transfer: 
Immuno-Blot Polyvinylidene fluoride (PVDF) membranes (Bio-Rad, Hercules, USA) and 
Whatman filter paper were cut to fit the size of the gels (8 x 6 cm) and (9 x 7 cm) respectively. 
The membranes were soaked in absolute methanol for a minute to activate the membranes. The 
membranes, the filter paper as well as the SDS PAGE gels were then soaked in transfer buffer 
for 10 min to equilibrate them for the protein transfer step. The transfer sandwich cassette was 
thus assembled by order; three layers of filter paper, a PVDF membrane, an SDS PAGE gel 
and three layers of filter paper. The sandwich was placed in the Trans-Blot Turbo Transfer 
System (Bio-Rad, Hercules, USA) cassette and the lid was locked. The transfer was set to a 1.5 
mm gel transfer for 10 min at 25 V. 
Following the transfer step, the PVDF membrane was carefully removed from the sandwich 
and submerged in Ponceau S stain, on a Stuart Gyro-Rocker SSL3 (Sigma-Aldrich, St. Louis, 
USA) orbital shaker at 50 rpm for 10 min. The membrane was then removed from the stain and 
washed in distilled water until the background was clear of the red stain, an image was captured 
on a ChemiDoc MP (Bio-Rad, Hercules, USA), and the membrane was cut to size avoiding 
contact with the protein bands before submerging the blot into 1x tris buffered saline – 
tween20® (TBST) to reverse the red stain. 
3.7.3 Western blot analysis: 
In order to detect the protein of interest, the blot was incubated in 5% fat-free milk prepared in 
1x TBST to block the non-specific binding of proteins for 2 h on an orbital shaker. After 
blocking the blots were then washed with 1x TBST and incubated overnight with the specific 
primary antibody in 1x TBST, as per table 3.5 below, on an orbital shaker at 4 °C. The morning 
after, the blot was washed three times in 1x TBST in ten-minute intervals on an orbital shaker. 
The blot was then incubated in the secondary antibody (Table 3.6), specific to the primary 
antibody, with 2.5% fat-free milk made up in 1x TBST and 2 μL StrepTactin horseradish 
peroxidase (HRP) on an orbital shaker for 1.5 h at room temperature. 
Following incubation with the secondary antibody (Table 3.6) the proteins of interest were 
detected using a LumiGLO Chemiluminescent Substrate Kit (ThermoFischer Scientific™, 
Massachusetts, USA). A working solution was prepared from the detection kit, with 1-part 
peroxide solution and 1-part Luminol/enhancer solution. The membrane was therefore 
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submerged in the working solution for 5 min in a dark place, as the substrate is light sensitive, 
and the blots were imaged on a ChemiDoc MP (Bio-Rad, Hercules, USA). 
Once the blots were imaged and the proteins were detected, they were washed in 1x TBST for 
2 min before the membranes were stripped. Thereafter, the blots were submerged in stripping 
buffer and incubated for 8 min at room temperature on an orbital shaker. The blots were then 
removed from the stripping buffer and washed twice in five-minute intervals with PBS, and 
washed twice more with 1x TBS in five-minute intervals. The stripped membranes were then 
blocked in 5% fat-free milk for 2 h and incubated overnight with another primary antibody. 
The next morning the blots were incubated for 1.5 h with the respective secondary antibody in 
2.5% fat-free milk at room temperature. β-Actin was used to normalise samples of the in vitro 
model and β-Tubulin was used to normalise the samples of the in vivo model, as β-Actin was 
regulated in the mouse liver samples. The blots were detected and imaged, the stripping was 
repeated for a maximum of three antibodies per blot (two stripping sessions per blot). The band 
intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). The 
fold change was calculated using the equation: fold change	=	( treatment	-	normal control
normal control
) and the 
treatments were compared to the control which was set at 1. 
Table 3.5 List of western blot primary antibodies. 
Antibody Supplier Source Cat. no. Pathway Mwt 
[AKT]  
Protein  





Rabbit  9272 Adipokine 
signalling 
60 kDa 








































































Rabbit  4257 Insulin 
signalling 
85 kDa 





















































Table 3.6 List of western blot secondary antibodies. 
Antibody Reference/Supplier Source Cat. no. 
IgG  
Anti-Rabbit HRP-Linked 
Cell Signalling Technology 




Cell Signalling Technology 





3.8 Statistical analysis: 
The data is presented as mean ± standard error of the mean (SEM) (n ³ 3, unless stated 
otherwise). The comparison among the groups of the raw data from the biochemical assays, 
Western blots and mRNA expression were analysed using one-way ANOVA followed by 
Tukey’s multiple comparisons test, Using GraphPad Prism version 7.00 for Macintosh, 
GraphPad Software, La Jolla California USA, www.graphpad.com. The differences were 





4.1 In vitro biochemical assays and staining techniques 
4.1.1 Cell viability (MTT) and lipid analysis (ORO) 
The MTT assay data (Figure 4.1) illustrates a significant reduction in cell mitochondrial 
activity with the oleic acid-induced control (p < 0.05). This reduction was also seen with the 
various treatments when compared to the normal control, except for pioglitazone 30 μM, 
Afriplex GRT 10 and 100 μg/mL treatments. No significant changes were observed when 
comparing the various treatments to the induced control. Barring the significant decrease in 
mitochondrial activity, the cells still expressed over 70% mitochondrial activity, suggesting 
that both the induction period with oleic acid and subsequent treatment with Afriplex GRT and 
pioglitazone was not cytotoxic. 
 
  
Figure 4.1 MTT assay, showing the effects of steatosis induction [1 mM oleic acid] along 
with the effects of anti-steatotic effects of various treatments with pioglitazone and/or 
Afriplex GRT (GRT), on cell viability. Data represented as mean ± SEM (n = 3), where *P 
< 0.05,
 




Oil red O data (Figure 4.2) illustrates a significant increase in lipid content for the induced 
control (p < 0.01) when compared to the normal control. Subsequent treatment with 
pioglitazone showed a slight decrease in lipid content when compared to the induced control. 
Treatment with Afriplex GRT induced a slight but dose-dependent reduction in lipid content 
when compared to the induced control. A significant reduction in lipid content was observed 
following two of the combination treatments (pioglitazone 30 μM + Afriplex GRT 1 μg/ml and 

















Figure 4.2 Oil red O assay, showing the effects of steatosis induction [1 mM oleic acid] along with the anti-steatotic effects of various treatments with 
pioglitazone and/or Afriplex GRT (GRT), on lipid accumulation. Images are a representation of one experiment, captured at 200x magnification using a 
Nikon Eclipse Ti/S light microscope (scale represents: 100μm). Histogram illustrates spectrophotometric data of three independent repeats of the destained 
section oil red O assay. Data represented as mean ± SEM (n = 3), where **P < 0.01 when compared to the normal control and 
#
P < 0.05, when compared 




4.1.2 Mitochondrial depolarisation (JC-1) 
Figure 4.3 illustrates data generated from exposing the treated cells to a lipophilic cationic 
fluorescent dye; 5,5,6,6’‐tetrachloro‐ 1,1’,3,3’‐tetraethylbenzimi‐dazoylcarbocyanine iodide 
(JC‐1), which serves as an indicator of mitochondrial membrane potential (mitochondrial 
depolarisation). Healthy cells such as the normal control in this study showed an intense red 
fluorescence, this is expected as the dye enters the mitochondria and forms J-aggregates that 
change the fluorescent property of the JC-1 dye. Unhealthy cells such as the induced control in 
the study show an intense green fluorescence, as the dye does not form J-aggregates due to its 
low mitochondrial membrane potential and the dye remains in its monomeric form. Therefore, 
the higher the ratio of green to red fluorescence the higher the depolarisation of mitochondrial 
membrane. Densitometric data shown by the histogram shows a significant reduction in red 
fluorescence when comparing the induced control to the normal control (p < 0.0001). This 
reduction was also seen across the various treatments, whereas Afriplex GRT 100 μg/mL and 
the highest dose of the combination treatment (pioglitazone 30 μM + Afriplex GRT 100 
μg/mL) slightly improved the condition when compared to the normal control (p < 0.001). 
Interestingly, treatment with Afriplex GRT 100 μg/mL and the highest dose of the combination 
treatment (pioglitazone 30 μM + Afriplex GRT 100 μg/mL) showed a significant increase in 
red fluorescence when compared to the induced control (p < 0.0001), suggesting that the 
treatment with Afriplex GRT 100 μg/mL restored the mitochondrial membrane potential when 
compared to the induced control with no additive effects from pioglitazone 30 μM. However, 















Figure 4.3 JC-1 assay, showing the effects of steatosis induction [1 mM oleic acid] along with the anti-steatotic effects of various treatments with 
pioglitazone and/or Afriplex GRT (GRT), on mitochondrial depolarisation. Images are a representation of one experiment, captured at 200x magnification 
using a Nikon Eclipse Ti/S Fluorescence Microscope (scale represents: 100μm). Histogram illustrates densitometric quantification data from the images 
captured following the JC-1 assay. The red fluorescence shown in the images was quantified using ImageJ32.app software. Data represented as mean ± 





4.2 In vitro mRNA expression (qRT-PCR) 
Figure 4.4 illustrates differences in the mRNA expression data of genes involved 
 in lipid metabolism, fold change was calculated using the equation: 
fold change	=	( treatment	-	normal control
normal control
) and the treatments were compared to the control which was 
set at 1. Figure 4.4 (a) AMPK-a is shown to be significantly down-regulated by Afriplex GRT 
100 μg/mL treatment (p < 0.05), when compared to the induced control, and no other 
significant differences were observed. ChREBP in Figure 4.4 (b) showed a significant 
upregulation with the induced control (p < 0.05), when compared to the normal control, and 
treatment with pioglitazone 30 μM (p < 0.05), Afriplex GRT 10 μg/mL (p < 0.01) as well as 
the highest concentration of the combination treatment (pioglitazone 30 μM + Afriplex GRT 
100 μg/mL) (p < 0.01) showed a significant down-regulation when compared to the induced 
control. FASN in Figure 4.4 (c) also showed a significant upregulation with the induced control 
when compared to the normal control (p < 0.05), however, no other significant differences were 
observed. SREBF1 in Figure 4.4 (d) showed a slight upregulation with the induced control 
when compared to the normal control, but the difference was insignificant. Treatment with 
pioglitazone 30 μM and Afriplex GRT 100 μg/mL showed a significant down-regulation when 





Figure 4.4 (a) AMPK-a mRNA expression of C3A cell-lysates normalised to b-actin, showing 
the effects of 24 h steatosis induction [1 mM oleic acid] along with the anti-steatotic effects of 
various treatments with pioglitazone and/or Afriplex GRT (GRT). Data represented as mean ± 






Figure 4.4 (b) ChREBP mRNA expression of C3A cell-lysates normalised to b-actin, showing 
the effects of 24 h steatosis induction [1 mM oleic acid] along with the anti-steatotic effects of 
various treatments with pioglitazone and/or Afriplex GRT (GRT). Data represented as mean ± 
SEM (n = 3), where *P < 0.05, when compared to the normal control and #P < 0.05, ##P < 0.01 






Figure 4.4 (c) FASN mRNA expression of C3A cell-lysates normalised to b-actin, showing the 
effects of 24 h steatosis induction [1 mM oleic acid] along with the anti-steatotic effects of 
various treatments with pioglitazone and/or Afriplex GRT (GRT). Data represented as mean ± 





Figure 4.4 (d) SREBF1 mRNA expression of C3A cell-lysates normalised to b-actin, showing 
the effects of 24 h steatosis induction [1 mM oleic acid] along with the anti-steatotic effects of 
various treatments with pioglitazone and/or Afriplex GRT (GRT). Data represented as mean ± 




Figure 4.5 data shows mRNA expression of genes involved in glucose metabolism and insulin 
signalling, fold change was calculated using the equation: fold change	=	( treatment	-	normal control
normal control
) 
and the treatments were compared to the control which was set at 1. GLUT2 in Figure 4.5 (a) 
showed a slight upregulation in expression due to oleic acid treatment in the induced control 
when compared to the normal control, but the difference was not significantly different. 
Treatment with the low dose combination treatment (pioglitazone 30 μM + Afriplex GRT 1 
μg/mL) showed a significant down-regulation when compared to the normal control (p < 0.01), 
and more so when compared to the induced control (p < 0.0001). Treatment with the high dose 
combination treatment (pioglitazone 30 μM + Afriplex GRT 100 μg/mL) significantly 
downregulated the mRNA expression of GLUT2 when compared with the induced control (p 
< 0.05). Further, G6PC in Figure 4.5 (b) was slightly down-regulated in the induced control 
when compared with the normal control, and across the various treatments when compared to 
the normal control except for the mid-dose combination treatment (pioglitazone 30 μM + 
Afriplex GRT 10 μg/mL), which was slightly upregulated when compared to the normal 
control. IRS-1 in Figure 4.5 (c) also showed a slight upregulation in the induced control when 
compared to the normal control however this was not significant. Treatment with Afriplex GRT 
interestingly showed a significant down-regulation when compared to the induced control (p < 
0.05), the trend was slightly dose-dependent although the significance was similar across the 
concentrations of Afriplex GRT. PCK1 in Figure 4.5 (d) showed no significant differences 
when comparing the induced control to normal control. Treatment with the low and mid-dose 
combination treatment (pioglitazone 30 μM + Afriplex GRT 1 μg/mL) (p < 0.01) and 
(pioglitazone 30 μM + Afriplex GRT 10 μg/mL) (p < 0.05), showed a significant upregulation 
when compared to both normal and induced controls, with the low dose combination treatment 





Figure 4.5 (a) GLUT2 mRNA expression of C3A cell-lysates normalised to b-actin, showing 
the effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 
treatments with pioglitazone and/or Afriplex GRT (GRT). Data represented as mean ± SEM (n 




P < 0.0001 when 






Figure 4.5 (b) G6PC mRNA expression of C3A cell-lysates normalised to b-actin, showing the 
effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 







Figure 4.5 (c) IRS-1 mRNA expression of C3A cell-lysates normalised to b-actin, showing the 
effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 
treatments with pioglitazone and/or Afriplex GRT (GRT). Data represented as mean ± SEM (n 
= 3), where 
#





Figure 4.5 (d) PCK1 mRNA expression of C3A cell-lysates normalised to b-actin, showing 
the effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 
treatments with pioglitazone and/or Afriplex GRT (GRT). Data represented as mean ± SEM 









No effect was observed with the mRNA expression data (Figure 4.6), of genes involved in lipid 
and glucose metabolism as well as oxidative stress, fold change was calculated using the 
equation: fold change	=	( treatment	-	normal control
normal control
) and the treatments were compared to the control 
which was set at 1. PPAR-a mRNA Figure 4.6 (a) was not affected by both the oleic acid-
induced stress and the various treatments. However, PPAR-g (Figure 4.6 (b)) was slightly 
upregulated in the induced control when compared to the normal control. Treatment with 
pioglitazone 30 μM reduced PPAR-g  when compared to both normal (p < 0.05) and induced 
controls (p < 0.01). Treatment with Afriplex GRT 10 μg/mL (p < 0.01) and Afriplex GRT 100 
μg/mL (p < 0.05) also showed a significant down-regulation when compared to the induced 
control, with Afriplex GRT 10 μg/ml being more significant. Interestingly the greater effect 
was observed following the high dose combination treatment (pioglitazone 30 μM + Afriplex 
GRT 100 μg/mL) when compared to both normal (p < 0.001) and induced controls (p < 0.0001). 
Treatment with Afriplex GRT 10 μg/mL and Afriplex GRT 100 μg/mL induced a significant 
reduction of SOD2 Figure 4.6 (c) when compared to the induced control (p < 0.01). Afriplex 
GRT 10 μg/mL, showed a significant upregulation of GPX2 Figure 4.6 (d) when compared to 






Figure 4.6 (a) PPAR-a mRNA expression of C3A cell-lysates normalised to b-actin, showing 
the effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 







Figure 4.6 (b) PPAR-g mRNA expression of C3A cell-lysates normalised to b-actin, showing 
the effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 
treatments with pioglitazone and/or Afriplex GRT (GRT). Data represented as mean ± SEM (n 













Figure 4.6 (c) SOD2 mRNA expression of C3A cell-lysates normalised to b-actin, showing the 
effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 
treatments with pioglitazone and/or Afriplex GRT (GRT). Data represented as mean ± SEM (n 
= 3), where 
##




Figure 4.6 (d) GPX2 mRNA expression of C3A cell-lysates normalised to b-actin, showing 
the effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 
treatments with pioglitazone and/or Afriplex GRT (GRT). Data represented as mean ± SEM 




4.3 In vitro protein expression (Western blotting) 
Figure 4.7 shows the protein expression of C3A for the proteins involved in lipid and  
glucose metabolism, fold change was calculated using the equation: 
fold change	=	( treatment	-	normal control
normal control
) and the treatments were compared to the control which was 
set at 1. pAKT/AKT ratio in Figure 4.7 (a) showed no significant differences when comparing 
the induced control to normal control. Treatment with pioglitazone 30 μM showed a significant 
upregulation when compared to the induced control (p < 0.05). Treatment with Afriplex GRT 
10 μg/mL significantly down-regulated pAKT/AKT ratio when compared to the normal control 
(p < 0.05), while interestingly, treatment with Afriplex GRT 10 μg/mL showed an even greater 
significant down-regulation when compared to the normal control and induced control (p < 
0.0001). This was also seen with the low dose combination treatment (pioglitazone 30 μM + 
Afriplex GRT 1 μg/mL), were pAKT/AKT ratio was significantly down-regulated when 
compared to the normal (p < 0.0001) and the induced controls (p < 0.01), respectively. The 
same was observed with the mid-dose combination treatment (pioglitazone 30 μM + Afriplex 
GRT 10 μg/mL) as pAKT/AKT ratio was significantly down-regulated when compared to the 
normal (p < 0.0001) and the induced controls (p < 0.001), respectively. pAMPK-a/AMPK-a 
ratio in Figure 4.7 (b) showed no significant difference with the induced control when 
compared to the normal control. However, treatment with Afriplex GRT 10 μg/mL 
significantly upregulated pAMPK-a/AMPK-a ratio when compared to both normal (p < 0.01) 
and induced controls (p < 0.05). No other significant differences observed across the various 





Figure 4.7 (a) pAKT/AKT ratio protein expression of C3A cell-lysates normalised to b-actin, 
showing the effects of 24 h steatosis induction [1 mM oleic acid] along with the and the anti-steatotic 
effects of various treatments with pioglitazone and/or Afriplex GRT (GRT). Images are a 
representation of one experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). 
Histogram illustrates densitometric quantification data from the images captured following the 
Western blot analysis. The band intensity of the blots was quantified using an ImageLab™ software 
v6.0.1 (Bio-Rad.com). Data represented as mean ± SEM (n = 4), where *P < 0.05, ****P < 0.0001 








P < 0.0001 when 
compared to the induced control. Lane 1: Control, lane 2: induced control, lane 3: Pio 30 µM, lane 
4: GRT 1 µg/mL, lane 5: GRT 10 µg/mL, lane 6: GRT 100 µg/mL, lane 7: Pio + GRT 1 µg/mL, 






Figure 4.7 (b) pAMPK-a/AMPK-a ratio protein expression of C3A cell-lysates normalised to b-
actin, showing the effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects 
of various treatments with pioglitazone and/or Afriplex GRT (GRT). Images are a representation of 
one experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. The 
band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 
Data represented as mean ± SEM (n = 4), where **P < 0.01 when compared to the normal control 
and 
#
P < 0.05 when compared to the induced control. Lane 1: Control, lane 2: induced control, lane 
3: Pio 30 µM, lane 4: GRT 1 µg/ml, lane 5: GRT 10 µg/mL, lane 6: GRT 100 µg/mL, lane 7: Pio + 





Figure 4.7 (c) MLYCD protein expression of C3A cell-lysates normalised to b-actin, showing the 
effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 
treatments with pioglitazone and/or Afriplex GRT (GRT). Images are a representation of one 
experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. The 
band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 
Data represented as mean ± SEM (n = 4). Lane 1: Control, lane 2: induced control, lane 3: Pio 30 
µM, lane 4: GRT 1 µg/mL, lane 5: GRT 10 µg/mL, lane 6: GRT 100 µg/mL, lane 7: Pio + GRT 1 




Protein expression data (Figure 4.8) from C3A lysates of proteins involved in apoptosis, 
oxidative stress and inflammatory response, fold change was calculated using the equation: 
fold change	=	( treatment	-	normal control
normal control
) and the treatments were compared to the control which was 
set at 1. Oleic acid-induced stress (induced control) significantly down-regulated the 
expression of Caspase-3 in Figure 4.8 (a) when compared with the normal control (p < 0.0001). 
The various treatments also induced a significant down regulation of capsase-3 when compared 
to the control, however no significant differences were observed when compared to the induced 
control. GSTZ-1 in Figure 4.8 (b) showed a significant upregulation with the induced control 
when compared to the normal control (p < 0.0001). Interestingly, the various treatments showed 
a significant down regulation when compared to both normal and induced controls, except for 
the high dose combination treatment (pioglitazone 30 μM + Afriplex GRT 100 μg/mL), which 
was only significantly down regulated when compared to the induced control and not the 
normal control. TNF-a in Figure 4.8 (c) expression showed a slight down regulation with the 
induced control when compared to the normal control although the data was not significantly 
different. Treatment with Afriplex GRT 1 μg/mL (p < 0.05) and Afriplex GRT 10 μg/mL (p < 
0.01) showed a significant down regulation of TNF-a expression when compared to the normal 
control. This was also seen with the low and mid dose combination treatments (pioglitazone 
30 μM + Afriplex GRT 1 μg/mL) and (pioglitazone 30 μM + Afriplex GRT 10 μg/mL), as the 







Figure 4.8 (a) Caspase-3 protein expression of C3A cell-lysates normalised to b-actin, showing the 
effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 
treatments with pioglitazone and/or Afriplex GRT (GRT). Images are a representation of one 
experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. The 
band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 
Data represented as mean ± SEM (n = 4), where **P < 0.01, ***P < 0.001, ****P < 0.0001 when 
compared to the normal control. Lane 1: Control, lane 2: induced control, lane 3: Pio 30 µM, lane 
4: GRT 1 µg/mL, lane 5: GRT 10 µg/mL, lane 6: GRT 100 µg/mL, lane 7: Pio + GRT 1 µg/mL, 






Figure 4.8 (b) GSTZ-1 protein expression of C3A cell-lysates normalised to b-actin, showing the 
effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 
treatments with pioglitazone and/or Afriplex GRT (GRT). Images are a representation of one 
experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. The 
band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 
Data represented as mean ± SEM (n = 4), where *P < 0.05, ***P < 0.001, ****P < 0.0001 when 
compared to the normal control and
 ####
P < 0.0001 when compared to the induced control. Lane 1: 
Control, lane 2: induced control, lane 3: Pio 30 µM, lane 4: GRT 1 µg/mL, lane 5: GRT 10 µg/mL, 
lane 6: GRT 100 µg/mL, lane 7: Pio + GRT 1 µg/mL, lane 8: Pio + GRT 10 µg/mL, lane 9: Pio + 




Figure 4.8 (c) TNF-a protein expression of C3A cell-lysates normalised to b-actin, showing the 
effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 
treatments with pioglitazone and/or Afriplex GRT (GRT). Images are a representation of one 
experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. The 
band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 
Data represented as mean ± SEM (n = 4), where *P < 0.05, **P < 0.01, ***P < 0.001 when compared 
to the normal control. Lane 1: Control, lane 2: induced control, lane 3: Pio 30 µM, lane 4: GRT 1 
µg/mL, lane 5: GRT 10 µg/mL, lane 6: GRT 100 µg/mL, lane 7: Pio + GRT 1 µg/mL, lane 8: Pio + 




Figure 4.9 shows the protein expression from C3A lysates of proteins involved in insulin 
signalling as well as lipid and glucose metabolism, fold change was calculated using the 
equation: fold change	=	( treatment	-	normal control
normal control
) and the treatments were compared to the control 
which was set at 1. IRS-1 in Figure 4.9 (a) was significantly upregulated by oleic acid treatment 
(induced control) when compared with the normal control (p < 0.05). Interestingly, the various 
treatments significantly downregulated protein expression of IRS-1 when compared to the 
induced control, except for Afriplex GRT 1 μg/mL, which did not significantly regulate IRS-1 
expression when compared to both controls. Pi3K in Figure 4.9 (b) expression was also showed 
to be significantly upregulated for the induced control when compared to the normal control (p 
< 0.001) while the various treatments were able to significantly downregulate Pi3K protein 
expression when compared to the induced control. PPAR-g in Figure 4.9 (c) expression showed 
a slight downregulation by the induced control when compared to the normal control although 
the difference was not significantly different. Treatment with Afriplex GRT 1 μg/mL showed 
a significant upregulation when compared to the induced control (p < 0.01). Treatment with 
the mid-dose combination treatment (pioglitazone 30 μM + Afriplex GRT 10 μg/mL) showed 





Figure 4.9 (a) IRS-1 protein expression of C3A cell-lysates normalised to b-actin, showing the 
effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 
treatments with pioglitazone and/or Afriplex GRT (GRT). Images are a representation of one 
experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. 
The band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 







P < 0.0001 when compared to the induced control. Lane 1: Control, 
lane 2: induced control, lane 3: Pio 30 µM, lane 4: GRT 1 µg/mL, lane 5: GRT 10 µg/mL, lane 6: 
GRT 100 µg/mL, lane 7: Pio + GRT 1 µg/mL, lane 8: Pio + GRT 10 µg/mL, lane 9: Pio + GRT 






Figure 4.9 (b) Pi3K protein expression of C3A cell-lysates normalised to b-actin, showing the 
effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects various treatments 
with pioglitazone and/or Afriplex GRT (GRT). Images are a representation of one experiment, 
captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates densitometric 
quantification data from the images captured following the Western blot analysis. The band 
intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). Data 







P < 0.0001 when compared to the induced control. Lane 1: Control, lane 
2: induced control, lane 3: Pio 30 µM, lane 4: GRT 1 µg/mL, lane 5: GRT 10 µg/mL, lane 6: GRT 





Figure 4.9 (c) PPAR-g protein expression of C3A cell-lysates normalised to b-actin, showing the 
effects of 24 h steatosis induction [1 mM oleic acid] and the anti-steatotic effects of various 
treatments with pioglitazone and/or Afriplex GRT (GRT). Images are a representation of one 
experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. 
The band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 
Data represented as mean ± SEM (n = 4), where *P < 0.05, when compared to the normal control 
and 
 ##
P < 0.01 when compared to the induced control. Lane 1: Control, lane 2: induced control, 
lane 3: Pio 30 µM, lane 4: GRT 1 µg/mL, lane 5: GRT 10 µg/mL, lane 6: GRT 100 µg/mL, lane 7: 




4.4 In vivo metabolic parameters 
4.4.1 Body weight gain and liver weights 
Figure 4.10 shows the percentage weight gain over time measured weekly for 10 weeks 
between the groups of mice used in the study, Figure 4.10 (a). The data shows significant 
changes in the various treatment groups at week 1 of treatment when compared to the lean 
control group, with the exception of the mice treated with Pioglitazone 15 mg/kg. This is 
expected as, from week 2 to week 10, significant increases in body weight by percentage was 
observed with the obese control as well as across the various treatment groups when compared 
to the lean control group. This is due to the genetic mutation of the leptin-receptor (Leprdb) of 
these obese mice that results in loss of satiety leading to increased food intake, obesity and 
spontaneous development of diabetes overtime as shown by the data in Figure 4.10 (a). No 
significant changes were exhibited when comparing the various treatment groups to the obese 
control. At termination mice livers were weighed according to their groups and the data was 
plotted on a histogram represented by Figure 4.10 (b). Data shows a significant increase in 
liver weight for the obese control group when compared to the lean control group (p < 0.05). 
Interestingly, treatment with Pioglitazone 15 mg/kg (p < 0.001), Afriplex GRT 74 mg/kg (p < 
0.01) and Afriplex GRT 740 mg/kg (p < 0.01) showed an even greater increase in liver weight 
compared to the obese control and when compared to the lean control. No significant changes 







Figure 4.10 (a) Effect of pioglitazone and GRT on total body weight % measured overtime and (b) liver weights measured at termination for lean (db/+), 
untreated and treated obese (db/db) mice, which received daily oral doses of pioglitazone 15 mg/kg and Afriplex GRT (GRT) at 74 or 740 mg/kg/body 
weight (BW) for 10 weeks. Data expressed as mean ± SEM of eight mice per group, where *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001, 




4.4.2 Oral glucose tolerance test (OGTT) 
Figure 4.11 shows an assessment of an oral glucose tolerance test conducted on the various 
experimental groups. A line graph was formulated from the data over time in Figure 4.11 (a) 
and an area under the curve analysis was formulated and illustrated in Figure 4.11 (b). Obese 
control mice presented with a significant increase in blood glucose (p < 0.0001) when 
compared to the lean control. Mice treated with pioglitazone 15 mg/kg showed a significant 
increase in glucose levels (p < 0.01) when compared to the lean control but less so than the 
obese control (p = 0.5191). This was also observed with the treatment with Afriplex GRT 74 
mg/kg (p < 0.01) and Afriplex GRT 740 mg/kg (p < 0.05), as a significant increase in glucose 
levels was observed when compared to the lean control in a dose-dependent manner. No 









Figure 4.11 (a) Effect of pioglitazone and GRT on oral glucose tolerance for lean (db/+), untreated and treated obese (db/db) mice, which received daily 
oral doses of pioglitazone 15 mg/kg and Afriplex GRT (GRT) at 74 or 740 mg/kg body weight (BW) for 10 weeks. Data expressed as mean ± SEM of 




4.4.3 Histological analysis (H&E Staining) 
Histological assessment of H&E stained liver sections Figure 4.12 of lean (db/+) and obese 
(db/db) mice across the different treatment groups. Normal hepatocytes should exhibit typical 
polygonal shape with a pink granular cytoplasm. In contrast, larger (hypertrophic) rounded 
hepatocytes with clear reticular cytoplasm, substantial lipid inclusions (ballooning), is 
considered evidence of steatosis. Thus, this criteria was used to determine significant 
morphological changes in the various treatment groups of the H&E stained liver sections. 
Histology of the lean non-diabetic mouse liver demonstrated normal morphology and including 
the presence of some lipid droplets. The obese control (db/db) showed a substantially different 
morphology when compared to the lean control (db/+) with increased lipid accumulation 
(steatosis) observed with the swelling of the hepatocytes. The intracellular lipid droplets 
included larger coalescence lipid droplets, classified as mixed medio-microvesicular steatosis. 
Treatment with pioglitazone 15 mg/kg substantially improved the lipid accumulation pattern 
to a microvesicular steatotic pattern (smaller lipid droplets) when compared to the obese 
control (db/db). Treatment with Afriplex GRT 74 mg/kg and 740 mg/kg further reduced lipid 
accumulation, however, the difference was still not comparable to the lean control.  
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Figure 4.12 Liver histopathology of lean (db/+), untreated and treated obese (db/db) mice, which 
received daily oral doses of pioglitazone 15 mg/kg and Afriplex GRT (GRT) at 74 or 740 
mg/kg/body weight (BW) for 10 weeks. Liver sections stained with haematoxylin and eosin (H&E). 
Liver sections were captured at 200x magnification using a Nikon Eclipse Ti/S Light Microscope 




4.5 In vivo mRNA expression (qRT-PCR) 
Figure 4.13 illustrates graphs generated from mRNA expression data of genes  
involved in lipid metabolism, fold change was calculated using the equation: 
fold change	=	( treatment	-	normal control
normal control
) and the treatments were compared to the control which was 
set at 1. In Figure 4.13 (a) Chrebp was shown to be significantly down-regulated in obese mice 
along with the various treatment groups, when compared to the lean control group (p < 0.0001). 
Pioglitazone 15 mg/kg (p < 0.001) and Afriplex GRT 740 mg/kg (p < 0.05) treatment 
significantly down-regulated Chrebp expression when compared to the obese control group. 
FASN in Figure 4.13 (b) was significantly down-regulated in the obese mice group along with 
the various treatment groups when compared to the lean control (p < 0.0001). Pioglitazone 15 
mg/kg (p < 0.001) and Afriplex GRT 740 mg/kg (p < 0.05) treatment down-regulated Fasn 
expression when compared to the obese control. Srebf1 in Figure 4.13 (c) was significantly 
down-regulated in the obese mice when compared to the lean control group (p < 0.0001) and 
the pioglitazone 15 mg/kg (p < 0.0001) and Afriplex GRT 740 mg/kg (p < 0.001) treatment led 





Figure 4.13 (a) Chrebp mRNA expression of in vivo NAFLD model liver tissue lysates normalised 
to Hprt, showing the expression in the lean and obese controls and the effects of mono treatments 
with pioglitazone or Afriplex GRT (GRT). Data represented as mean ± SEM (n = 3), where ****P 







Figure 4.13 (b) Fasn mRNA expression of in vivo NAFLD model liver tissue lysates normalised to 
Hprt, showing the expression in the lean and obese controls and the effects of mono treatments with 
pioglitazone or Afriplex GRT (GRT). Data represented as mean ± SEM (n = 3), where ****P < 






Figure 4.13 (c) Srebf1 mRNA expression of in vivo NAFLD model liver tissue lysates normalised 
to Hprt, showing the expression in the lean and obese controls and the effects of mono treatments 
with pioglitazone or Afriplex GRT (GRT). Data represented as mean ± SEM (n = 3), where ****P 
< 0.0001 when compared to the lean control; ###P < 0.001 and ####P < 0.0001 when compared to the 




Figure 4.14, demonstrates the mRNA expression data of genes involved in glucose metabolism 
and insulin signalling, fold change was calculated using the equation: 
fold change	=	( treatment	-	normal control
normal control
) and the treatments were compared to the control which was 
set at 1. Glut2 in Figure 4.14 (a) showed a slight downregulation in the obese control and low 
dose Afriplex GRT [74 mg/kg] groups, however, the difference was not significant, when 
compared to the lean control group. Mice treated with pioglitazone 15 mg/kg (p < 0.0001) and 
Afriplex GRT 740 mg/kg (p < 0.001) showed a significant downregulation of GLUT2 when 
compared to the lean control, in addition a significant down-regulation was observed when 
compared to the obese control (p < 0.01) and (p < 0.05), respectively. Irs-1 in Figure 4.14 (b) 
showed a significant down regulation in the obese control, and across the various treatment 
groups when compared to the lean control (p < 0.0001). No significant change was observed 
when comparing the various treatments to the obese control. Ppar-g  in Figure 4.14 (c) showed 
a slight upregulation by both low and high dose of Afriplex GRT treatments when compared 
to the lean control, however this was not significant. No change was observed in the obese 
control, when compared to the lean control and the pioglitazone 15 mg/kg treatment group 





Figure 4.14 (a) Glut2 mRNA expression of in vivo NAFLD model liver tissue lysates normalised 
to Hprt, showing the expression in the lean and obese controls and the effects of mono treatments 
with pioglitazone or Afriplex GRT (GRT). Data represented as mean ± SEM (n = 3), where ***P < 
0.001, ****P < 0.0001 when compared to the lean control; #P < 0.05 and ##P < 0.01 when compared 






Figure 4.14 (b) Irs-1 mRNA expression of in vivo NAFLD model liver tissue lysates normalised to 
Hprt, showing the expression in the lean and obese controls and the effects of mono treatments with 
pioglitazone or Afriplex GRT (GRT). Data represented as mean ± SEM (n = 3), where ****P < 





Figure 4.14 (c) Ppar-g mRNA expression of in vivo NAFLD model liver tissue lysates normalised 
to Hprt, showing the expression in the lean and obese controls and the effects of mono treatments 




The mRNA expression data (Figure 4.15) of genes involved in apoptosis (Casp 3), lipid and 
glucose metabolism (PPAR-α) as well as an oxidative stress response (SOD2), fold change was 
calculated using the equation: fold change	=	( treatment	-	normal control
normal control
) and the treatments were 
compared to the control which was set at 1. Casp3, Figure 4.15 (a) showed significant 
downregulation in the obese mice group along with the various treatment groups, when 
compared to the lean control group (p < 0.0001). Pioglitazone 15 mg/kg (p < 0.001) and 
Afriplex GRT 740 mg/kg (p < 0.01) treatment groups induced a significant down-regulation 
when compared to the obese control group. PPAR-a in Figure 4.15 (b) showed a significant 
down-regulation with the obese control, and across the various treatment groups when 
compared to the lean control (p < 0.0001). Mice treated with pioglitazone 15 mg/kg (p < 
0.0001) and Afriplex GRT 740 mg/kg (p < 0.001) showed a significant downregulation of 
SOD2 when compared to the lean control, furthermore a significant down-regulation was 






Figure 4.15 (a) Caspase-3 mRNA expression of in vivo NAFLD model liver tissue lysates 
normalised to Hprt, showing the expression in the lean and obese controls and the effects of mono 
treatments with pioglitazone or Afriplex GRT (GRT). Data represents Mean ± SEM (n = 3), where 
****P < 0.0001 when compared to the lean control; ##P < 0.01 and ###P < 0.001 when compared to 






Figure 4.15 (b) Ppar-a mRNA expression of in vivo NAFLD model liver tissue lysates normalised 
to Hprt, showing the expression in the lean and obese controls and the effects of mono treatments 
with pioglitazone or Afriplex GRT (GRT). Data represents Mean ± SEM (n = 3), where ****P < 





Figure 4.15 (c) Sod2 mRNA expression of in vivo NAFLD model liver tissue lysates normalised to 
Hprt, showing the expression in the lean and obese controls and the effects of mono treatments with 
pioglitazone or Afriplex GRT (GRT). Data represents Mean ± SEM (n = 3), where ***P < 0.001, 
****P < 0.0001 when compared to the lean control; #P < 0.05 and ##P < 0.01 when compared to the 




4.6 In vivo protein expression (Western blotting) 
In Figute 4.16, the expression of proteins involved in lipid and glucose metabolism from mouse 
liver lysates is iilustrated. The fold change was calculated using the equation: 
fold change	=	( treatment	-	normal control
normal control
) and the treatments were compared to the control which was 
set at 1. Obese control mice presented with a significant increase in pAKT/AKT ratio, Figure 
4.16 (a), when compared to the lean control (p < 0.001). Pioglitazone 15 mg/kg (p < 0.0001) 
treatment and Afriplex GRT 74 mg/kg (GRT 1) (p < 0.01) showed a significant down regulation 
when compared to the obese control. pAMPK-a/AMPK-a ratio in Figure 4.16 (b) showed a 
slight upregulation in the obese control when compared to the lean control, although no 
significance was observed, and subsequent treatment groups showed no significant differences 
when compared to both lean and obese controls. MLYCD in Figure 4.16 (c) treatment with 
pioglitazone 15 mg/kg showed a significant upregulation when compared to both lean (p < 
0.001) and obese controls (p < 0.01). Treatment with Afriplex GRT 740 mg/kg (GRT 2) 





Figure 4.16 (a) pAKT/AKT ratio protein expression of in vivo NAFLD model liver tissue lysates, 
normalised to b-tubulin, showing the expression in the lean and obese controls and the effects of 
mono treatments with pioglitazone or Afriplex GRT (GRT). Images are a representation of one 
experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. 
The band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 
Data represented as mean ± SEM (n = 4), where ***P < 0.001 when compared to the lean control; 
##P < 0.01 and ####P < 0.0001 when compared to the obese control. Lane 1 – 2 (Lean control), lane 







Figure 4.16 (b) pAMPK-a/AMPK-a ratio protein expression of in vivo NAFLD model liver tissue 
lysates, normalised to b-tubulin, showing the expression in the lean and obese controls and the 
effects of mono treatments with pioglitazone or Afriplex GRT (GRT). Images are a representation 
of one experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram 
illustrates densitometric quantification data from the images captured following the Western blot 
analysis. The band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-
Rad.com). Data represented as mean ± SEM (n = 4). Lane 1 – 2 (Lean control), lane 3 – 5 (Obese 




Figure 4.16 (c) MLYCD protein expression of in vivo NAFLD model liver tissue lysates, 
normalised to b-tubulin, showing the expression in the lean and obese controls and the effects of 
mono treatments with pioglitazone or Afriplex GRT (GRT). Images are a representation of one 
experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. 
The band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 
Data represented as mean ± SEM (n = 4), where *P < 0.05, ***P < 0.001 when compared to the 
lean control; ##P < 0.01 when compared to the obese control. Lane 1 – 2 (Lean control), lane 3 – 5 





Expression of proteins from mouse liver lysates involved in apoptosis, oxidative stress, lipid 
and glucose metabolism as well as the inflammatory response is shown in Figure 4.17. The 
fold change was calculated using the equation: fold change	=	( treatment	-	normal control
normal control
) and the 
treatments were compared to the control which was set at 1. Caspase-3 in Figure 4.17 (a) 
showed a significant down regulation when comparing the obese control to the lean control (p 
< 0.0001). Subsequent treatment groups with the various treatments also showed a significant 
down regulation when compared to the lean control, with GRT 2 significantly upregulating 
Caspase-3 when compared to the obese control (p < 0.05). GSTZ-1 in Figure 4.17 (b) 
expression showed a slight upregulation in the obese control when compared to the lean 
control, however, this was not significant and subsequent treatment groups with the various 
treatment regiments showed no significant differences when compared to both lean and obese 
controls. PPAR-a expression in Figure 4.17 (c) showed a slight upregulation in the obese 
control when compared to the lean control although the difference was not significant. 
Treatment with pioglitazone 15 mg/kg showed a significant upregulation when compared to 
the lean control (p < 0.05) while treatment with both doses of Afriplex GRT showed no 
significant differences when compared to both lean and obese controls. TNF-a expression in 
Figure 4.17 (d) showed no difference between the obese and the lean controls. Treatment with 
GRT 2 showed a significant down regulation when compared to both the lean (p < 0.001) and 





Figure 4.17 (a) Caspase-3 protein expression of in vivo NAFLD model liver tissue lysates, 
normalised to b-tubulin, showing the expression in the lean and obese controls and the effects of 
mono treatments with pioglitazone or Afriplex GRT (GRT). Images are a representation of one 
experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. The 
band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 
Data represented as mean ± SEM (n = 4), where ****P < 0.0001 when compared to the lean control 
and #P < 0.05 when compared to the obese control. Lane 1 – 2 (Lean control), lane 3 – 5 (Obese 






Figure 4.17 (b) GSTZ-1 protein expression of in vivo NAFLD model liver tissue lysates, normalised 
to b-tubulin, showing the expression in the lean and obese controls and the effects of mono 
treatments with pioglitazone or Afriplex GRT (GRT). Images are a representation of one 
experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. The 
band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 
Data represented as mean ± SEM (n = 4). Lane 1 – 2 (Lean control), lane 3 – 5 (Obese control), lane 






Figure 4.17 (c) PPAR-a protein expression of in vivo NAFLD model liver tissue lysates, normalised 
to b-tubulin, showing the expression in the lean and obese controls and the effects of mono 
treatments with pioglitazone or Afriplex GRT (GRT). Images are a representation of one 
experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. The 
band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 
Data represented as mean ± SEM (n = 4), where *P < 0.05 when compared to the lean control. Lane 
1 – 2 (Lean control), lane 3 – 5 (Obese control), lane 6 – 8 (Pio 15 mg/kg), lane 9 – 11 (GRT 74 






Figure 4.17 (d) TNF-a protein expression of in vivo NAFLD model liver tissue lysates, normalised 
to b-tubulin, showing the expression in the lean and obese controls and the effects of mono 
treatments with pioglitazone or Afriplex GRT (GRT). Images are a representation of one 
experiment, captured using a ChemiDoc MP (Bio-Rad, Hercules, USA). Histogram illustrates 
densitometric quantification data from the images captured following the Western blot analysis. The 
band intensity of the blots was quantified using an ImageLab™ software v6.0.1 (Bio-Rad.com). 
Data represented as mean ± SEM (n = 4), where ***P < 0.001 when compared to the lean control 
and ###P < 0.001, when compared to the obese control. Lane 1 – 2 (Lean control), lane 3 – 5 (Obese 




4.7 Key findings  
In C3A cells oleic acid induced significant amounts of intracellular lipid accumulation, as 
confirmed by the ORO assay. An MTT assay showed that the oleic acid treated cells retained 
over 70% mitochondrial activity, thus suggesting that the effect of treatment was not cytotoxic. 
Several genes involved in lipid and carbohydrate metabolism including ChREBP, FASN and 
SREBF1 were significantly down-regulated by pioglitazone and Afriplex GRT treatment. 
SOD2 and GSTZ-1, genes and proteins involved in hepatic oxidative stress were also down-
regulated by Afriplex GRT and pioglitazone, suggestive of reduced hepatic oxidative stress in 
vitro. Protein expression of TNF-a and Caspase-3 was down-regulated by Afriplex GRT and 
pioglitazone, showing reduced inflammation and apoptosis. Afriplex GRT at the highest 
concentration prevented mitochondrial depolarisation induced by oleic acid. No apparent 
beneficial effects on oleic acid-induced steatosis by co-treatment of pioglitazone and Afriplex 
GRT was observed. 
As expected the db/db mice were hyperglycaemic and obese at ten weeks. At necropsy the 
obese mice showed increased liver weights when compared to the lean control. The OGTT 
showed an improved glucose tolerance by treatment with Afriplex GRT in a dose-dependent 
manner. The H&E stained liver sections confirmed the NAFLD model by observed steatotic 
changes in the tissue architecture when comparing to the lean control. Pioglitazone treatment 
showed to reduce the size and abundance of lipid droplets. Afriplex GRT at the low dose 
reduced hepatocyte ballooning. The mRNA expression of Chrebp, Fasn and Srebf1 was down-
regulated by treatment with pioglitazone and Afriplex GRT. The mRNA and protein expression 
of Sod2 and GSTZ-1, was down-regulated by Afriplex GRT and pioglitazone, indicating signs 
of reduced hepatic oxidative stress, similar to the in vitro model. The protein expression of 
TNF-a and Caspase-3 was also down-regulated by Afriplex GRT and pioglitazone, suggesting 






5.1 Establishment of NAFLD Models 
Hepatic steatosis, better described as increased hepatic lipid accumulation, results from an 
increased infiltration and accumulation of FFAs into the hepatocytes 1. This increased flux of 
lipids into the liver is also known as fatty liver disease, and in the absence of alcohol the disease 
is termed as non-alcoholic fatty liver disease 8. In order to mimic this ailment in vitro, C3A 
liver cells were exposed to oleic acid as described in subsection 3.2.1. Data obtained from the 
Oil red O (ORO) assay confirmed the presence of NAFLD in the induced control, which 
presented with a significant increase in intracellular lipid accumulation when compared to the 
normal control.  
An MTT assay was performed parallel to the ORO to analyse the mitochondrial dehydrogenase 
activity within the model, measuring the overall cell metabolic activity and providing an 
approximation of the cell viability (Figure 4.1). The percentage viability of the cells was 
slightly decreased when compared to the uninduced normal control, this reduction in MTT 
activity by FFAs has previously been seen in MCF-7 cells by Pacheco et al. 155. Barring the 
significant decrease in mitochondrial dehydrogenase activity, the cells still expressed over 70% 
mitochondrial activity, suggesting that the induction period with oleic acid was not toxic to the 
C3A liver cells, previously seen in a study by Jeong et al. 156. 
In vivo, the study made use of tissue samples obtained from C57BL/6 lean (db/+) and obese 
(db/db) male mice, a known animal model of NAFLD 6. The obese mice showed significantly 
increased body weight over time and increased liver weights compared to their lean 
counterparts, suggesting an increase of FFAs into mice hepatic cells (Figure 4.10 (a) & (b)). 
Histological analysis confirmed a substantially different morphology when comparing the 
obese to the lean liver sections with increased lipid levels observed with the swelling of the 
hepatocytes as well as an increase in lipid droplet size and steatotic pattern classification 
(Figure 4.12). These are known characteristics of steatosis and the steatosis severity was 
confirmed through histological scoring, a method described by Trak-Smayra et al. 152. Indeed, 
intracellular microvesicular, mediovesicular and microvacuolar lipid accumulation was 
observed in the obese mice, therefore, confirming the in vivo NAFLD model. 
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5.2 Effect of treatment on lipid and glucose utilisation by assessment of metabolic activity 
in models of NAFLD 
Patients with dyslipidaemia and diabetes, express increased level of FFAs and glucose in their 
circulation, and are at increased risk for the development of NAFLD 36. Insulin and glucose 
signalling play roles in de novo lipogenesis through sterol regulatory element-binding 
transcription factor 1 (SREBF1) and carbohydrate-response element-binding protein 
(ChREBP) pathways, respectively 157. SREBF1 and ChREBP are major transcriptional 
regulators that induce key lipogenic enzymes such as FASN to promote lipogenesis in the liver. 
The role of ChREBP in regulating the transcription of genes related to glucose and lipid 
metabolism has been shown in the development of hepatic steatosis, via dyslipidaemia and 
glucose intolerance 158. Both in vitro and in vivo mRNA expression of transcriptional regulators 
SREBF1 and ChREBP, were down-regulated by treatment with pioglitazone and Afriplex GRT 
when compared to the oleic acid-induced/obese control (Figure 4.4 (b) & (d)) and Figure 4.13 
(a) & (c)). The ORO data showed reduced lipid accumulation in the in vitro model by treatment 
with pioglitazone and Afriplex GRT (Figure 4.2). The use of treatment in combination showed 
an even greater reduction, suggesting that there may have been an additive effect by both 
regiments. The downstream mRNA expression of FASN was also down-regulated by treatment, 
suggesting that the mechanism by which Afriplex GRT reduces hepatic lipid content could be 
explained by the suppression of the above mentioned transcriptional regulators that induce 
lipogenic enzymes 159 (Figure 4.4 (c) and Figure 4.13 (b)).  
The significant body weight gain over time in the in vivo model suggests increased lipogenesis 
and when comparing the data to the liver weights measured at terminations, the data confirms 
the translocation of excess fat into the hepatocytes (Figure 4.10 (a) & (b)). Histological analysis 
supports this as the H&E stained liver sections of the obese mice showed classical signs of 
hepatic steatosis 152. In contrast, liver sections from obese mice treated with Afriplex GRT 
showed decreased steatosis when compared to the obese untreated control liver sections, the 
improved architecture of the liver suggest that Afriplex GRT may ameliorate hepatic steatosis, 
similarly reported by Beltrán-Debón R et al. 131 (Figure 4.12). Mice treated with pioglitazone, 
showed increased liver weight when compared to the liver weight of the obese control mice. 
However, with the histological analysis, an improvement was observed in liver architecture 
when compared to the obese control, suggesting that the drug reverses steatosis in the liver. 
The use of pioglitazone has been previously reported to enhance weight gain in patients with 
T2DM 160, thus supporting the increased liver weight observed in this study. The 
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overexpression of PPAR-a leads to the regulation of energy homeostasis by the expression of 
genes involved in fatty acid beta-oxidation 161. In this study, it was found that in vivo mRNA 
expression of PPAR-a was significantly down-regulated by treatment with pioglitazone and 
Afriplex GRT, in comparison to the lean control (Figure 4.15 (b)). The mRNA expression of 
PPAR-a was not assessed in vitro, which is a limitation to the findings in the study. In addition 
to the mRNA expression, PPAR-a was found to be overexpressed in the mice treated with 
pioglitazone, at the protein level (Figure 4.17 (c)), suggesting that treatment with the drug 
induced the binding of multiple ribosomes, thereby increasing expression of the PPAR-a 
protein and subsequently inducing a lipolytic pathway in vivo 162. 
The overexpression of active protein kinase B (pAKT) in the liver increases lipid synthesis 
which in turn results in NAFLD and hypertriglyceridemia 163. Protein expression data from the 
in vitro model showed that treatment with Afriplex GRT reduced the AKT activity by 
pAKT/AKT ratio in a dose-dependent manner, when compared to both controls (Figure 4.7 
(a)). This suppression of active AKT was similarly observed in the in vivo model by treatment 
with pioglitazone and Afriplex GRT (Figure 4.16 (a)). These results suggest that suppression 
of active AKT may have facilitated the reduction of lipid content by treatment with Afriplex 
GRT in both models of NAFLD, which is in agreement with the findings by Mazibuko-Mbeje 
et al. 164. Malonyl-CoA decarboxylase (MLYCD) is an enzyme that is responsible for the 
reaction that converts malonyl-CoA to acetyl-CoA, which contributes to the breakdown of fatty 
acids. A study by An et al., showed rats fed a high-fat diet had hepatic insulin resistance and 
hepatic lipid accumulation, ultimately ameliorated by the hepatic overexpression of MLYCD 
165. Therefore, a similar trend with the in vivo model was observed by the overexpression of 
MLYCD at the protein level with pioglitazone and Afriplex GRT treatment (Figure 4.16 (c)). 
This observation suggests that the treatment with pioglitazone and Afriplex GRT works via the 
overexpression of MLYCD, in vivo, subsequently ameliorating hepatic lipid accumulation. To 
the best of our knowledge this is the first study to report on the overexpression of MLYCD, in 
vivo by treatment with Afriplex GRT. 
Alternatively, active 5' adenosine monophosphate-activated protein kinase (AMPK-a) 
improves glucose uptake, lowering blood glucose levels by increasing the utilisation of stored 
fat in the body, ultimately decreasing blood triglyceride levels 78. In vivo, OGTT data showed 
that obese mice were less tolerant to glucose than their lean counterparts, confirming poor 
utilisation of glucose with the diseased model (Figure 4.11 (a) & (b)). Subsequent treatment 
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with pioglitazone and Afriplex GRT slightly enhanced glucose utilisation, however, no 
significances were observed when compared to their lean counterparts. At the protein level the 
expression of active AMPK-a showed no significant differences in the in vivo model, however 
the treatment with the low dose Afriplex GRT slightly upregulated active AMPK-a, in 
comparison to the lean control (Figure 4.16 (b)). The in vitro model showed that treatment with 
Afriplex GRT at a concentration of 10 µg/ml had a significant increase in pAMPK-a/AMPK-
a ratio (Figure 4.7 (b)). Collectively the data observed from both models illustrate how active 
AMPK-a works in lipid reduction and how improved glucose utilisation is facilitated by 
treatment with Afriplex GRT, reported by Mazibuko-Mbeje et al. 164.  
Glucose utilisation is a key factor in the development of NAFLD to NASH, where NASH is 
related to insulin resistance with a higher output of fatty acids and glucose to the liver 166. De 
novo lipogenesis subsequently converts glucose into triglycerides contributing to hepatic 
steatosis. Silva et al., showed that the overexpression of glucose transporter (GLUT2) in mice 
fed a high fat diet contributed to the development of NASH by facilitated glucose uptake to 
hepatocytes 167. The mRNA expression of Glut2 was down-regulated in the in vivo treated with 
pioglitazone and Afriplex GRT (Figure 4.14 (a)). Additionally, co-treatment with pioglitazone 
and Afriplex GRT, in vitro, significantly down regulated GLUT2 expression (Figure 4.5 (a)), 
which is suggestive of an additive effect by both treatments in combination, thus aiding in 
ameliorating hepatic lipid accumulation by suppressing facilitated glucose input into the 
hepatocytes. Glucose-6-phosphatase (G6PC) is an integral membrane protein of the 
endoplasmic reticulum, key in regulating the homeostasis of blood glucose concentrations by 
catalysing the hydrolysis of D-glucose 6-phosphate to D-glucose and orthophosphate, 
essentially providing recycled glucose to the cytoplasm of neutrophils to maintain normal 
function 168. In this study, the mRNA expression of G6PC was reduced by the effects of 
steatosis induction with oleic acid in the in vitro model (Figure 4.5 (b)). However, treatment 
with pioglitazone or Afriplex GRT showed no significant changes. Thus, suggesting that the 
mode of action at which the treatments ameliorated hepatic lipid accumulation had no role in 




5.3 Effect of treatment on insulin signalling pathways in models of NAFLD 
Numerous molecular and physiological changes occur during insulin resistance, resulting in 
the accumulation of lipids within the liver 12. Insulin-dependent activation of AKT via 
phosphoinositide 3 kinase (PI3K) in the liver stimulates the storage of glucose as glycogen and 
regulates the pathways which suppress gluconeogenesis 163. Moreover, dysfunctional AKT is 
associated with insulin resistance as well as impaired glucose tolerance 169. In this study, the 
protein expression of PI3K was significantly down-regulated by treatment with pioglitazone 
and Afriplex GRT in the in vitro model (Figure 4.9 (b)). Therefore, suggesting that the 
suppression of PI3K contributed to a reduction of glucose uptake and increased fatty acid 
oxidation, thus leading to the reduction in hepatic lipid accumulation and gluconeogenesis, 
similarly reported by Mazibuko et al. 144. 
Conventionally, lipid accumulation in hepatocytes is a result of obesity, as well as insulin 
resistance through, which there is an increased release of FFAs from adipocytes 13. The rise in 
insulin and glucose levels in the circulation triggers de novo fatty acid synthesis, contributing 
to the abnormal retention of FFAs in hepatocytes 71,72. When insulin binds to the insulin 
receptor substrate (IRS) its tyrosine kinase is activated through phosphorylation. IRS-1 is 
abundantly expressed in hepatocytes and tyrosine-phosphorylated IRS-1 bind to and activate 
PI3K, subsequently activating a serine/threonine kinase AKT 170. AKT-dependent 
phosphorylation of forkhead box-containing protein O subfamily-1 (FOXO1) suppresses the 
expression of G6PC resulting in the inhibition of hepatic glucose output 170,171. Insulin also 
stimulates the pathway by the upregulation of FASN thereby increasing hepatic lipogenesis 
170,172. In vitro, the upregulation of IRS-1 in both mRNA and protein expression (Figure 4.5 (c) 
and Figure 4.9 (a)) was seen by induction with oleic acid, this stimulates the upregulation of 
FASN confirming the increase of hepatic lipid content with the induced control. Subsequent 
treatment with either pioglitazone or Afriplex GRT as well as the combination treatment 
thereof showed a down-regulation of IRS-1 with both the mRNA and protein expression. 
Therefore, suggesting that the suppressed expression of IRS-1 had caused a downstream 
inhibition of lipogenic enzymes, ultimately reducing hepatic steatosis in the in vitro model. 
The in vivo model had shown that the (db/db) mice had a low expression of Irs-1 mRNA when 
compared to the lean control and no effect was seen from using various treatment (Figure 4.14 
(b)). This result was expected because the db/db mouse model has previously been shown to 
be insulin resistant 173. Due to the model variation, it therefore implied that the treatment 
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reduced the activity of lipogenic genes using different pathways for the in vivo model compared 
to the in vitro model. 
In literature, pioglitazone has been classified as a PPAR-γ agonist which decreases the release 
of FFAs through storage of triglycerides in adipose tissues. Pioglitazones’ action on PPAR-γ 
inhibits the production of proinflammatory cytokines primarily on white adipose tissue and 
reduces lipid accumulation by improving insulin sensitivity in the liver 174. The mRNA 
expression of PPAR-γ in both the in vitro and in vivo models of NAFLD was down-regulated 
by treatment with pioglitazone, and Afriplex GRT (Figure 4.6 (b) and Figure 4.14 (c)). The 
combination treatment in the in vitro model showed an even greater down-regulation of PPAR-
γ mRNA expression, therefore suggesting that there may have been an additive effect by both 
regiments. At the protein level, PPAR-γ expression showed to be significantly upregulated in 
the in vitro model (Figure 4.9 (c)). Therefore, the low expression at gene level and subsequent 
upregulation at the protein level suggests that Afriplex GRT may have induced the binding of 
multiple ribosomes, thereby increasing expression of the PPAR-γ protein 162.  
5.4 Effect of treatment on oxidative stress markers involved in the pathophysiology of 
NAFLD 
Hepatic oxidative stress is considered a “second hit” in the pathogenesis of NASH. In NAFLD, 
mitochondrial dysfunction, peroxisomal and microsomal fatty acid oxidation and lipid 
peroxidation are the major generators of excessive amounts of ROS 14. Superoxide dismutase 
and glutathione peroxidase are antioxidant enzymes that protect against oxidative damage 
caused by free radical attack 127,175. In vitro mRNA expression of SOD2 was significantly 
down-regulated by treatment with Afriplex GRT when compared to the induced control (Figure 
4.6 (c)), signifying a reduction in antioxidant enzyme expression and potentially a reduction in 
enzyme activity contributing to reduced hepatic oxidative stress. Diabetes causes the 
production of free radicals in large amounts, this, in turn, results in the increased expression of 
antioxidant enzymes 176. In contrast, the mRNA expression of Sod2 was significantly down-
regulated by treatment with pioglitazone and Afriplex GRT, in the db/db model (Figure 4.15 
(c)). These results suggest that both in vitro and in vivo models presented with a reduction in 
antioxidant enzyme activity after treatment, aiding in the prevention of cellular damage. 
Alternatively, the mRNA expression of glutathione peroxidase (GPX2) was upregulated by the 
induction with oleic acid in vitro (Figure 4.6 (d)). Subsequent treatment with pioglitazone and 
Afriplex GRT showed no significant reduction, therefore suggesting that the in vitro model 
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alleviated hepatic oxidative stress by following a pathway different to GPX2, as seen with the 
reduction in SOD2 mRNA expression. At the protein level, GSTZ-1 was significantly 
upregulated by induction with oleic acid in the in vitro model (Figure 4.8 (b)), however, a 
significant down-regulation of GSTZ-1 was observed by treatment with pioglitazone, Afriplex 
GRT and the combination treatments. This suggests that indeed the induction of hepatic 
steatosis with oleic acid induced hepatic oxidative stress to the in vitro model, as reported by 
Garcia-Ruiz et al. 177. Subsequent treatment reduced the expression of GSTZ-1, thus 
suppressing the abundance of the antioxidant enzyme and its function in alleviating ROS. In 
the in vivo model, a similar reduction in GSTZ-1 was seen, by treatment with Afriplex GRT at 
a protein level (Figure 4.17 (b)), therefore in both in vitro and in vivo models Afriplex GRT 
facilitated the reduction in oxidative stress caused by fat infiltration into the liver by reduced 
expression levels of GSTZ-1, similarly to the findings by Jiang et al. 178. 
5.5 Mechanistical analysis of treatment against hepatic steatosis by assessment of 
inflammatory response markers 
The cascade of events highlighted by the progression of the disease is linked to the NF-κB, 
TNF-α and IL-6, which are the major pro-inflammatory cytokines that regulate innate and 
adaptive immune responses 85,88. This activates a cascade of downstream inflammatory 
signalling kinases, namely; inhibitor kappa B kinase and C-Jun-N-terminal kinase 89. At the 
protein level, TNF-α expression was significantly down-regulated by the treatment with 
Afriplex GRT in both in vitro and in vivo models (Figure 4.8 (c) and Figure 4.17 (d)). This 
result was expected as Afriplex GRT has been previously reported to have anti-inflammatory 
properties 25, therefore, suggesting that Afriplex GRT protects against hepatic inflammation by 
its action on inflammatory cytokines 127,132. 
5.6 The effect of treatment on pro-apoptotic markers involved in NAFLD pathogenesis  
Malhi et al., conducted a study that highlighted how hepatic lipoapoptosis was exhibited 
throughout the pathogenesis of NAFLD in several models using monounsaturated and 
saturated fatty acids as a mode of induction 100. The JC-1 dye selectively enters the 
mitochondria of cells and changes colour from green to red due to change in the mitochondrial 
membrane potential and as such, healthy cells fluoresce red and unhealthy cells fluoresce green 
149. The observed decrease in mitochondrial membrane potential indicated by the JC-1 assay 
as cell fluorescence changed from green to red when compared to the induced control suggests 
induction of apoptosis via the intrinsic pathway in cells treated with Afriplex GRT (Figure 4.3). 
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In the in vivo model, the mRNA expression of Caspase-3 was down-regulated in the (db/db) 
obese mice (Figure 4.15 (a)), while subsequent treatment with pioglitazone and Afriplex GRT 
had no significant effect. A similar trend was observed by both the in vitro and in vivo models 
at a protein level and both models of hepatic steatosis had not experienced apoptosis (Figure 
4.8 (a) and Figure 4.17 (a)), in fact, the expression of Caspase-3 was reduced compared to the 
normal controls, which is suggestive of an anti-apoptosis response, similarly reported by 
Flanagan et al. 179. Contrasting this statement, the treatment with the high dose Afriplex GRT 
in the in vivo model resulted in an upregulation of caspase-3 when compared to the obese 
control, suggesting that Afriplex GRT at a high dose may have pro-oxidant and pro-apoptotic 
activity. 
 
Figure 5.1: Mechanistic summary of experimentally induced NAFLD models in response to mono/co-
treatment with Afriplex GRT and/or pioglitazone. SREBF1 – Sterol regulatory element-binding factor-
1, ChREBP – Carbohydrate-response element-binding protein, FASN – Fatty acid synthase, PPAR-a 
– Peroxisome proliferator-activated receptor a, AKT – Protein kinase B, MLYCD – Malonyl-CoA 
Decarboxylase, TNF-a – Tumour necrosis factor a, GLUT2 – Glucose transporter 2, SOD2 – 
Superoxide dismutase 2, GSTZ-1 – Glutathione S-transferase Zeta 1, PI3K – Phosphoinositide 3-






The study hypothesised that Afriplex GRT could mitigate hepatic steatosis and aimed at 
investigating the hepatoprotective effects of Afriplex GRT and pioglitazone against hepatic 
oxidative stress, apoptosis and inflammation in an in vitro and in vivo model of NAFLD. 
Oleic acid induced hepatic steatosis in C3A liver cells was dose-dependently reduced by 
Afriplex GRT, more so by its combination with pioglitazone. The mechanism by which 
Afriplex GRT reduced hepatic lipid content in both models was observed by the suppression 
of transcriptional regulators SREBF1 and ChREBP, which in turn suppressed the expression of 
lipogenic enzymes. The overexpression of PPARa and MLYCD proteins may have led to the 
induced activity of a lipolytic pathway in vivo, supporting the histological reduction in lipid 
droplets observed from treatment with Afriplex GRT. 
The insulin signalling cascade plays an important role in hepatic homeostasis mediated by  
IRS-1 and persistent insulin signalling in the liver is shown to promote lipogenesis by the 
conversion of excess glucose into hepatic fatty acids. Oleic acid induction overexpressed  
IRS-1 and IRS-1 in vitro, causing a downstream upregulation of FASN. Afriplex GRT 
subsequently reversed the effects caused by oleic acid-induced hepatic steatosis by suppression 
of IRS-1 and IRS-1 expression, thereby suppressing the expression of lipogenic enzymes in 
this model. The db/db mouse model showed signs of insulin resistance by a reduced Irs-1 
mRNA expression, leading to the reduced activity of lipogenic genes in a pathway other than 
the insulin signalling cascade. On the contrary a reduction in Glut2 mRNA expression was seen 
by treatment with Afriplex GRT, indicating a possible suppression in hepatic facilitated 
glucose input. 
The increased expression of antioxidant enzymes (SOD2, GPX2 and GSTZ-1) prior treatment 
indicated an increased enzyme activity linked to hepatic oxidative stress. Although these 
enzymes may not serve as markers of oxidative stress per se, treatment with Afriplex GRT 
suppressed antioxidant enzymes SOD2 and GSTZ-1, in both models. The differential 
expression of the antioxidant enzymes caused by Afriplex GRT in this study has, therefore, 
showed potential to possibly enhance the reduction in oxidative stress caused by hepatic fat 
infiltration.  
At the protein level, the expression of TNF-α was significantly down-regulated by treatment 
with Afriplex GRT in both in vitro and in vivo models of NAFLD. Therefore, the suppression 
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in TNF-α expression suggests and that Afriplex GRT has potential in alleviating the 
progression of hepatic steatosis to steatohepatitis by its action on inflammatory cytokines. 
The observed decrease in mitochondrial membrane potential indicated by the JC-1 assay as 
cell fluorescence changed from red to green by the induced control suggests an induction of 
apoptosis via the intrinsic pathway in cells treated with oleic acid. The mRNA expression of 
Caspase-3, in vivo, showed to be down regulated by treatment with pioglitazone and Afriplex 
GRT. At a protein level, models of hepatic steatosis showed a down regulation of the 
executioner caspase (Caspase-3) when compared to the normal control, thereby suggesting that 
capsase-3 is down-regulated in hepatic steatosis. However, treatment with the highest dose of 
Afriplex GRT in vivo resulted in an up-regulation of caspase-3 when compared to the obese 
control. Therefore, Afriplex GRT at a high dose may possess pro-apoptotic activities even in 
hepatic steatosis. 
7. Concluding Remark and Future Perspectives 
Altogether, this study confirmed the modulatory benefits of Afriplex GRT as a potential 
therapeutic agent for NAFLD by its action on both in vitro and in vivo models. Limitations 
were identified in certain aspects of the study, which unfortunately led to inconclusive findings. 
Gene and protein expressions of antioxidant enzymes related to hepatic oxidative stress were 
analysed, which do not necessarily account for the enzyme activity. Instead, oxidative stress 
markers could have assessed, using high throughput assays for more conclusive results, 
therefore this issue will be further investigated. A wider range of inflammatory markers could 
also be assessed, in order to fully elucidate the mechanism of action Afriplex GRT has on 
hepatic steatosis. Although subject to further analysis, the herbal extract shows promise in 
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9.4 List of materials 
Table 9.1 List of materials and suppliers. 
Product  Supplier/Company  
(ca 12%) Aspalathin-rich Afriplex 
GRT 
Afriplex, Paarl, Western Cape, RSA 
1.5ml centrifuge tubes  Sigma-Aldrich, Saint Louis, USA  
10x Tris/Glycine/SDS  Bio-Rad, Berkeley, California, USA  
12% Mini-PROTEAN® TGX™ 
Stain-free FastCast Acrylamide kit  
Bio-Rad, Berkeley, California, USA  
15ml Centrifuge tubes  NEST Biotechnology Co. LTD, Jiangsu, China  
2ml Cryo-vials  Corning, MA, USA  
2ml Safe-lock tubes  Eppendorf, Hamburg, Germany  
50ml Centrifuge tubes  NEST Biotechnology Co. LTD, Jiangsu, China  
5x TransBlot® Turbo Transfer 
Buffer, RTA Transfer Kit, LF PVDF  
Bio-Rad, Berkeley, California, USA  
Bovine serum albumin (BSA) – 
fatty-acid free 
Capricorn scientific Auf der Lette 13A, 
Ebsdorfergrund, Germany 
C3A human liver cells American Type Culture Collection, Manassas, USA 
Calcium chloride (CaCl2) Sigma-Aldrich, Saint Louis, USA 
Carbon dioxide (CO2) Air Products, Centurion, Gauteng, RSA 
Cell counting chamber slides Life Technologies Corporation, Carlsbad, CA, USA 
Citric acid monohydrate Sigma-Aldrich, Saint Louis, USA 
Clarity™ Western C ECL Substrate Bio-Rad, Berkeley, California, USA 
Corning® 500ml Bottle Top 
Vacuum Filter 
Corning Inc, New York, USA 
Crystal violet Merck, Whitehouse Station, NJ, USA 
Dexamethasone Sigma-Aldrich, Saint Louis, USA 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich, Saint Louis, USA 
Dithiothreitol Sigma-Aldrich, Saint Louis, USA 
Dulbecco’s phosphate saline buffer 
(DPBS) 
Lonza, Walkersville, MD, USA 
Eagle’s Minimum Essential Medium 
(EMEM) 
Lonza, Walkersville, MD, USA 
Ethyl alcohol Sigma-Aldrich, Saint Louis, USA 
Ethylenediaminetetraacetic acid 
disodium salt dihydrate (EDTA) 
Sigma-Aldrich, Saint Louis, USA 
Foetal bovine serum (FBS) Lonza, Walkersville, MD, USA 
Glass Pasteur Pipettes Lasec, Marienfeld, Germany 
Glucose Standard 1 Wako Chemicals, Osaka, Japan 
Glucose Standard 2 Wako Chemicals, Osaka, Japan 




Thermo Fisher Scientific™, Johannesburg, Gauteng, 
RSA 
Isopropanol Sigma-Aldrich, Saint Louis, USA 
L-Glutamine Lonza, Walkersville, MD, USA 




Substrate Kit  
Cell Signaling Technology, Boston, USA 
Magnesium chloride (MgCl2) Sigma-Aldrich, Saint Louis, USA 
Methanol VWR Chemicals, Fontenay-sous-Bois, France 
Millex-GP syringe filter unit Millipore PES membrane, Merck 
NON-CELLBIND -96 well plates Corning, MA, USA 
NON-CELLBIND -6 well plates Corning, MA, USA 
Oil O Red Sigma-Aldrich, Saint Louis, USA 
p-Nitrophenyl phosphate disodium 
salt hexahydrate 
Sigma-Aldrich, Saint Louis, USA 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific™, Johannesburg, Gauteng, 
RSA 
Ponceau S Stain Sigma-Aldrich, Saint Louis, USA 
Potassium Chloride (KCl) Sigma-Aldrich, Saint Louis, USA 
Precision Protein™ StrepTactin-
HRP Conjugate 
Bio-Rad, Berkeley, California, USA 
Protease Inhibitors Roche, Basel, Switzerland 
Restore Plus Western blot stripping 
buffer 
Thermo Fisher Scientific™, Johannesburg, Gauteng, 
RSA 
Scintillation vials CJ Labs, Johannesburg, Gauteng, RSA 
Serological pipettes -2ml Corning, MA, USA 
Serological pipettes-10ml Corning, MA, USA 
Serological pipettes-25ml Corning, MA, USA 
Serological pipettes-50ml Corning, MA, USA 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich, Saint Louis, USA 
Sodium chloride (NaCl) Sigma-Aldrich, Saint Louis, USA 
Sodium citrate tribasic dihydrate Sigma-Aldrich, Saint Louis, USA 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, Saint Louis, USA 
Sodium hydroxide (NaOH) Sigma-Aldrich, Saint Louis, USA 
Stainless steel beads Qiagen, Hilden, Germany 
Sterile TC water Lonza, Walkersville, MD, USA 
T75 (75cm2) Flasks Greiner bio-one, Frickenhausen, Germany 
TissueLyser Qiagen, Hilden, Germany 
Trizma® base Sigma-Aldrich, Saint Louis, USA 
Trypan blue Invitrogen, Carlsbad, CA, USA 
Trypsin-versene Lonza, Walkersville, MD, USA 
Tween-20 Sigma-Aldrich, Saint Louis, USA 




9.5 Preparation of buffers and reagents: 
1 x Transfer buffer for Semi-dry Western blot: A 1 x transfer buffer was prepared by mixing 
200 ml of 5 x TransBlot® Turbo Transfer Buffer with 600 ml distilled water and 200 ml 
absolute ethanol.  
1 x Tris-buffered saline Tween-20 (TBST): A 1 L solution of TBST was prepared by mixing 
100 ml 10 x TBS with 900 ml distilled water and 1 ml Tween-20. The buffer was kept at 4°C.  
10 x Tris-buffered saline (TBS) pH 7.6: To make 2 L of a 10 x TBS buffer, 48.44 g of 2-
Amino-2-(hydroxymethyl)-1,3-propanediol (Trizma® base) (Mw 121.14 g/mol) and 160.12 g 
of NaCl (Mw 58.44 g/mol) were dissolved in 2000 ml distilled water. The pH was adjusted to 
7.6 using concentrated hydrochloric acid. The buffer was kept at 4 °C.  
Crystal Violet solution: A 2 % (w/v) crystal violet stock solution was prepared by dissolving 
2 g of crystal violet powder with 100 ml distilled water. Thereafter, a 0.5 % (v/v) working 
solution was prepared by mixing 250 μl of the 2 % stock solution with 50 ml distilled water.  
Laemmli Buffer: A 2 x Laemmli Buffer is composed of 4 % SDS, 20 % glycerol, 10 % 2-
mercaptoethanol, 0.004 % bromphenol blue and 0.125 M Tris HCl at pH 6.8. The buffer was 
kept at 23 °C.  
MTT Reagent: A 2 mg/ml MTT reagent was prepared by dissolving 90 mg MTT in 45 ml 
PBS. The reagent was kept at 4 °C. 
Oil Red O (ORO) solution: A 1 % (w/v) ORO (Sigma-Aldrich, Saint Louis, USA) stock 
solution was prepared by dissolving 1 g ORO powder in 100 ml isopropanol. From the 1 % 
stock solution a 0,7 % (v/v) ORO working solution was prepared by mixing 7 ml ORO stock 
solution with 3 ml distilled water. The working solution was prepared fresh on the day of the 
assay and filtered using filter paper (pore size: 11 μl) 
Sorensons Buffer: Glycine (0,1 M) and NaCl (0,1 M) were dissolved in 100 ml cell culture 




Table 9.2 Preparation of RIPA buffer. 
Reagents Final Volume 
50 mM Tris (pH7.5) 2.5 μl 
1 mM DTT 0.008 g 
50 mM NaF 0.104 g 
100 μM Na3VO4 500 μl 
1% NP40 500 μl 
1% Triton X 144 500 μl 
25 μg/ml RNase 125 μl 
Protease inhibitor tablets 2 tablets 
Phosho inhibiting tablets 5 tablets 
Table 9.3 Preparation of 1.5 mm Bio-Rad (Hercules, USA) TGX Stain-free FastCast 
Acrylamide gel. 
 Stacking Gel Resolving Gel 
 x2 x3 x4 x6 x2 x3 x4 x6 
Gel % 4% 12% 
Solution A 2 ml 3 ml 4 ml 6 ml 6 ml 9 ml 12 ml 18 ml 
Solution B 2 ml 3 ml 4 ml 6 ml 6 ml 9 ml 12 ml 18 ml 
10% APS 20 μl 30 μl 40 μl 60 μl 60 μl 90 μl 120 μl 180 μl 
TEMED 4 μl 6 μl 8 μl 12 μl 6 μl 9 μl 12 μl 18 μl 
Total Volume 4 ml 6 ml 8 ml 12 ml 12 ml 18 ml 24 ml 36 ml 
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9.6 In vitro dose-dependent response to pioglitazone 
 
 
Figure 9.1 (a) MTT and (b) ORO assay showing the effects of steatosis induction [1mM oleic acid] 
along with the effects of anti-steatotic treatment using a range of pioglitazone treatments or Afriplex 
GRT (GRT), on cell viability and lipid accumulation. Data represents Mean ± SEM (n = 3), where 
*P < 0.05, **P < 0.01 and ***P < 0.001, when compared to the normal control; 
#
P < 0.05, 
##
P < 0.01, 
###
P < 0.001 and 
####
P < 0.0001 when compared to the induced control respectively.  
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Treatment with pioglitazone showed a significant decrease in mitochondrial activity in a dose-
dependent manner when compared to the normal control, with the exception of pioglitazone at 
20 μM. The data, although significant, showed no cytotoxicity with any treatment dose and this 
is evident as the mitochondrial activity of the C3A cells was above 70% throughout the various 
treatment concentrations. The same was observed when the cells were treated with Afriplex 
GRT. 
An Oil red O assay (Figure 8.1 (b)), expectedly showed a significant increase when comparing 
the normal control to cells which were treated with just 1 mM oleic acid (induced control). 
Subsequent treatment with pioglitazone showed a significant decrease in lipid accumulation 
when compared to the induced control, with the exception of pioglitazone at 10 μM. 
Interestingly lipid accumulation was most substantially reduced when the cells were treated 
with pioglitazone at 15 and 30 μM. Treatment with Afriplex GRT also showed a significant 
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